Parkinson disease
Parkinson disease (PD) is the most common neurodegenerative movement disorder. In Europe, prevalence and incidence rates for PD are estimated at approximately 108–257/100 000 and 11–19/100 000 per year, respectively. Risk factors include age, male gender and some environmental factors. The aetiology...
Uložené v:
| Vydané v: | European journal of neurology Ročník 27; číslo 1; s. 27 - 42 |
|---|---|
| Hlavní autori: | , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
England
John Wiley & Sons, Inc
01.01.2020
|
| Predmet: | |
| ISSN: | 1351-5101, 1468-1331, 1468-1331 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Parkinson disease (PD) is the most common neurodegenerative movement disorder. In Europe, prevalence and incidence rates for PD are estimated at approximately 108–257/100 000 and 11–19/100 000 per year, respectively. Risk factors include age, male gender and some environmental factors. The aetiology of the disease in most patients is unknown, but different genetic causes have been identified. Although familial forms of PD account for only 5%–15% of cases, studies on these families provided interesting insight on the genetics and the pathogenesis of the disease allowing the identification of genes implicated in its pathogenesis and offering critical insights into the mechanisms of disease. The cardinal motor symptoms of PD are tremor, rigidity, bradykinesia/akinesia and postural instability, but the clinical picture includes other motor and non‐motor symptoms. Its diagnosis is principally clinical, although specific investigations can help the differential diagnosis from other forms of parkinsonism. Pathologically, PD is characterized by the loss of dopaminergic neurons in the pars compacta of the substantia nigra and by accumulation of misfolded α‐synuclein, which is found in intra‐cytoplasmic inclusions called Lewy bodies. Currently available treatments offer good control of motor symptoms but do not modify the evolution of the disease. This article is intended to provide a comprehensive, general and practical review of PD for the general neurologist. |
|---|---|
| AbstractList | Parkinson disease (PD) is the most common neurodegenerative movement disorder. In Europe, prevalence and incidence rates for PD are estimated at approximately 108-257/100 000 and 11-19/100 000 per year, respectively. Risk factors include age, male gender and some environmental factors. The aetiology of the disease in most patients is unknown, but different genetic causes have been identified. Although familial forms of PD account for only 5%-15% of cases, studies on these families provided interesting insight on the genetics and the pathogenesis of the disease allowing the identification of genes implicated in its pathogenesis and offering critical insights into the mechanisms of disease. The cardinal motor symptoms of PD are tremor, rigidity, bradykinesia/akinesia and postural instability, but the clinical picture includes other motor and non-motor symptoms. Its diagnosis is principally clinical, although specific investigations can help the differential diagnosis from other forms of parkinsonism. Pathologically, PD is characterized by the loss of dopaminergic neurons in the pars compacta of the substantia nigra and by accumulation of misfolded α-synuclein, which is found in intra-cytoplasmic inclusions called Lewy bodies. Currently available treatments offer good control of motor symptoms but do not modify the evolution of the disease. This article is intended to provide a comprehensive, general and practical review of PD for the general neurologist.Parkinson disease (PD) is the most common neurodegenerative movement disorder. In Europe, prevalence and incidence rates for PD are estimated at approximately 108-257/100 000 and 11-19/100 000 per year, respectively. Risk factors include age, male gender and some environmental factors. The aetiology of the disease in most patients is unknown, but different genetic causes have been identified. Although familial forms of PD account for only 5%-15% of cases, studies on these families provided interesting insight on the genetics and the pathogenesis of the disease allowing the identification of genes implicated in its pathogenesis and offering critical insights into the mechanisms of disease. The cardinal motor symptoms of PD are tremor, rigidity, bradykinesia/akinesia and postural instability, but the clinical picture includes other motor and non-motor symptoms. Its diagnosis is principally clinical, although specific investigations can help the differential diagnosis from other forms of parkinsonism. Pathologically, PD is characterized by the loss of dopaminergic neurons in the pars compacta of the substantia nigra and by accumulation of misfolded α-synuclein, which is found in intra-cytoplasmic inclusions called Lewy bodies. Currently available treatments offer good control of motor symptoms but do not modify the evolution of the disease. This article is intended to provide a comprehensive, general and practical review of PD for the general neurologist. Parkinson disease (PD) is the most common neurodegenerative movement disorder. In Europe, prevalence and incidence rates for PD are estimated at approximately 108–257/100 000 and 11–19/100 000 per year, respectively. Risk factors include age, male gender and some environmental factors. The aetiology of the disease in most patients is unknown, but different genetic causes have been identified. Although familial forms of PD account for only 5%–15% of cases, studies on these families provided interesting insight on the genetics and the pathogenesis of the disease allowing the identification of genes implicated in its pathogenesis and offering critical insights into the mechanisms of disease. The cardinal motor symptoms of PD are tremor, rigidity, bradykinesia/akinesia and postural instability, but the clinical picture includes other motor and non‐motor symptoms. Its diagnosis is principally clinical, although specific investigations can help the differential diagnosis from other forms of parkinsonism. Pathologically, PD is characterized by the loss of dopaminergic neurons in the pars compacta of the substantia nigra and by accumulation of misfolded α‐synuclein, which is found in intra‐cytoplasmic inclusions called Lewy bodies. Currently available treatments offer good control of motor symptoms but do not modify the evolution of the disease. This article is intended to provide a comprehensive, general and practical review of PD for the general neurologist. Parkinson disease (PD) is the most common neurodegenerative movement disorder. In Europe, prevalence and incidence rates for PD are estimated at approximately 108–257/100 000 and 11–19/100 000 per year, respectively. Risk factors include age, male gender and some environmental factors. The aetiology of the disease in most patients is unknown, but different genetic causes have been identified. Although familial forms of PD account for only 5%–15% of cases, studies on these families provided interesting insight on the genetics and the pathogenesis of the disease allowing the identification of genes implicated in its pathogenesis and offering critical insights into the mechanisms of disease. The cardinal motor symptoms of PD are tremor, rigidity, bradykinesia/akinesia and postural instability, but the clinical picture includes other motor and non‐motor symptoms. Its diagnosis is principally clinical, although specific investigations can help the differential diagnosis from other forms of parkinsonism. Pathologically, PD is characterized by the loss of dopaminergic neurons in the pars compacta of the substantia nigra and by accumulation of misfolded α‐synuclein, which is found in intra‐cytoplasmic inclusions called Lewy bodies. Currently available treatments offer good control of motor symptoms but do not modify the evolution of the disease. This article is intended to provide a comprehensive, general and practical review of PD for the general neurologist. |
| Author | Balestrino, R. Schapira, A.H.V. |
| Author_xml | – sequence: 1 givenname: R. surname: Balestrino fullname: Balestrino, R. organization: University of Turin – sequence: 2 givenname: A.H.V. surname: Schapira fullname: Schapira, A.H.V. email: a.schapira@ucl.ac.uk organization: UCL Queen Square Institute of Neurology |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31631455$$D View this record in MEDLINE/PubMed |
| BookMark | eNp90DtPwzAQB3ALFdEHDP0CCIkFhrR3fiTOiKrykCpggNlyUkdySZ1iJ0L99hhaGCqBl_Pwu9Pdf0h6rnGGkDHCBOObGmcmyBHkERkgT2WCjGEv_pnARCBgnwxDWAEAzSickD7DlCEXYkDGz9q_WRcad7G0wehgTslxpetgzvZ1RF5v5y-z-2TxdPcwu1kkJcdcJjldgpQZp7TQQkqQvCpkhpKLAkwmBcUqFcIgFrnkhley1AxSnbIlo5wKYCNytZu78c17Z0Kr1jaUpq61M00XFGWQsTznWR7p5QFdNZ13cbuoKI1ncmBRne9VV6zNUm28XWu_VT_HRnC9A6VvQvCm-iUI6itIFYNU30FGOz2wpW11axvXem3r_zo-bG22f49W88f5ruMTodJ-Eg |
| CitedBy_id | crossref_primary_10_1007_s12031_020_01776_5 crossref_primary_10_1016_j_metabol_2024_156104 crossref_primary_10_1038_s41401_024_01259_y crossref_primary_10_3389_fnagi_2021_648151 crossref_primary_10_1111_cns_14883 crossref_primary_10_1007_s13760_024_02656_0 crossref_primary_10_1007_s11682_024_00867_w crossref_primary_10_3390_biomedicines12071391 crossref_primary_10_1002_fsn3_3792 crossref_primary_10_3390_ijms231911394 crossref_primary_10_1016_j_gastha_2022_12_005 crossref_primary_10_3390_electronics10141740 crossref_primary_10_2217_epi_2023_0190 crossref_primary_10_1097_WNF_0000000000000597 crossref_primary_10_1080_23279095_2025_2499856 crossref_primary_10_1016_j_pec_2023_107931 crossref_primary_10_1016_j_lfs_2022_121144 crossref_primary_10_3390_nu16020308 crossref_primary_10_3390_nu15153428 crossref_primary_10_1007_s10072_023_07173_1 crossref_primary_10_1016_j_mito_2022_05_001 crossref_primary_10_1016_j_neuro_2024_12_003 crossref_primary_10_1002_mdc3_13926 crossref_primary_10_1124_molpharm_122_000633 crossref_primary_10_5937_mckg57_49190 crossref_primary_10_3390_cells11091520 crossref_primary_10_3390_genes12111681 crossref_primary_10_1007_s10072_024_07422_x crossref_primary_10_1016_j_nrl_2023_11_007 crossref_primary_10_1002_jms_4952 crossref_primary_10_3390_biom12020340 crossref_primary_10_1055_s_0041_1733960 crossref_primary_10_1186_s13102_023_00642_2 crossref_primary_10_1007_s12035_023_03561_y crossref_primary_10_1016_j_ecoenv_2023_115565 crossref_primary_10_1152_jn_00307_2025 crossref_primary_10_3390_separations9080224 crossref_primary_10_1007_s10517_022_05542_y crossref_primary_10_1038_s41531_022_00363_2 crossref_primary_10_1007_s11042_025_20661_0 crossref_primary_10_1148_rg_230233 crossref_primary_10_1016_j_nicl_2025_103859 crossref_primary_10_1016_j_heliyon_2024_e35751 crossref_primary_10_1007_s40846_022_00691_x crossref_primary_10_3390_s24020662 crossref_primary_10_1007_s12035_024_04260_y crossref_primary_10_1111_jnc_14916 crossref_primary_10_3390_biom14080949 crossref_primary_10_1016_j_parkreldis_2025_107988 crossref_primary_10_3389_fpubh_2022_801109 crossref_primary_10_3390_pharmaceutics15030770 crossref_primary_10_3389_fncel_2025_1559151 crossref_primary_10_2147_JIR_S511645 crossref_primary_10_1038_s42003_024_06656_x crossref_primary_10_3389_fphar_2022_1028356 crossref_primary_10_1016_j_parkreldis_2021_02_003 crossref_primary_10_3390_biom11071001 crossref_primary_10_1016_j_mehy_2025_111660 crossref_primary_10_1016_S1875_5364_25_60800_4 crossref_primary_10_1007_s00701_024_06096_w crossref_primary_10_1177_20552076251352941 crossref_primary_10_3390_diagnostics13142394 crossref_primary_10_3390_cells13040296 crossref_primary_10_3233_JPD_212931 crossref_primary_10_3389_fnins_2021_690013 crossref_primary_10_1111_cns_13753 crossref_primary_10_1007_s10072_025_08189_5 crossref_primary_10_1002_mds_29047 crossref_primary_10_3390_medicina61010027 crossref_primary_10_1016_j_bbr_2024_115111 crossref_primary_10_1016_j_arr_2025_102693 crossref_primary_10_1016_j_phrs_2023_106874 crossref_primary_10_1080_00207454_2022_2074848 crossref_primary_10_1016_j_bcp_2021_114849 crossref_primary_10_3390_brainsci12020143 crossref_primary_10_1038_s41467_024_50718_x crossref_primary_10_1016_j_hermed_2023_100771 crossref_primary_10_1016_j_neulet_2023_137223 crossref_primary_10_1007_s00221_023_06735_1 crossref_primary_10_1007_s11845_024_03689_3 crossref_primary_10_1111_ner_13237 crossref_primary_10_1016_j_bspc_2022_104116 crossref_primary_10_1038_s41522_024_00535_3 crossref_primary_10_1016_j_nbd_2025_107042 crossref_primary_10_14201_rmc2021171515 crossref_primary_10_1111_cns_70541 crossref_primary_10_1016_j_snb_2021_131297 crossref_primary_10_3390_ijms232012699 crossref_primary_10_3390_bioengineering12010021 crossref_primary_10_1212_WNL_0000000000201010 crossref_primary_10_1007_s11033_024_09236_8 crossref_primary_10_3390_cells13090770 crossref_primary_10_1080_00914037_2024_2399271 crossref_primary_10_3389_fnins_2023_1329738 crossref_primary_10_3390_ijms25147721 crossref_primary_10_3389_fimmu_2021_795036 crossref_primary_10_3389_fnagi_2022_924784 crossref_primary_10_1080_01691864_2021_1948353 crossref_primary_10_3390_antiox12030753 crossref_primary_10_1016_j_neuint_2020_104823 crossref_primary_10_3389_fncom_2021_735991 crossref_primary_10_1002_biof_1936 crossref_primary_10_3390_cells12040651 crossref_primary_10_3390_brainsci13020157 crossref_primary_10_1080_09638288_2023_2219902 crossref_primary_10_1007_s43440_023_00530_z crossref_primary_10_1007_s12640_022_00558_8 crossref_primary_10_1007_s13760_021_01814_y crossref_primary_10_1159_000533362 crossref_primary_10_1038_s41589_024_01580_x crossref_primary_10_3389_fcell_2025_1577382 crossref_primary_10_1016_j_neuint_2024_105857 crossref_primary_10_1007_s00415_025_13230_w crossref_primary_10_1016_j_engappai_2023_106882 crossref_primary_10_3390_brainsci11060779 crossref_primary_10_1007_s11064_022_03713_x crossref_primary_10_3390_s21186301 crossref_primary_10_1016_j_phymed_2025_156462 crossref_primary_10_1097_itx_0000000000000049 crossref_primary_10_1038_s41598_023_49617_w crossref_primary_10_1021_acschemneuro_5c00496 crossref_primary_10_1007_s12035_022_02944_x crossref_primary_10_1016_j_ijbiomac_2025_146541 crossref_primary_10_3390_chemosensors11100523 crossref_primary_10_3390_molecules27144644 crossref_primary_10_3390_biom13121761 crossref_primary_10_1016_j_bbr_2023_114574 crossref_primary_10_3389_fimmu_2022_992505 crossref_primary_10_3389_fncom_2021_756881 crossref_primary_10_3390_biomedicines12051130 crossref_primary_10_3390_ijms26072918 crossref_primary_10_3390_ijms23031089 crossref_primary_10_1371_journal_pone_0327733 crossref_primary_10_1016_j_brainresbull_2024_110991 crossref_primary_10_1007_s12035_022_03102_z crossref_primary_10_3390_nu13030803 crossref_primary_10_3390_biomedicines9070717 crossref_primary_10_1016_j_prdoa_2025_100301 crossref_primary_10_1186_s40035_023_00372_y crossref_primary_10_1007_s12640_022_00630_3 crossref_primary_10_1016_j_biopha_2021_112389 crossref_primary_10_1007_s15016_023_3133_7 crossref_primary_10_3390_ijms241210328 crossref_primary_10_3233_NRE_210181 crossref_primary_10_3389_fcell_2022_837337 crossref_primary_10_1016_j_bspc_2025_107673 crossref_primary_10_3389_fnmol_2023_1232805 crossref_primary_10_1371_journal_pmed_1004092 crossref_primary_10_1007_s00210_024_03215_3 crossref_primary_10_1134_S002689332101009X crossref_primary_10_3390_jpm12030450 crossref_primary_10_3389_fnagi_2022_927625 crossref_primary_10_1016_j_jhazmat_2024_136215 crossref_primary_10_1016_j_parkreldis_2025_107341 crossref_primary_10_1016_j_neuro_2024_02_005 crossref_primary_10_1007_s00018_024_05262_8 crossref_primary_10_1117_1_NPh_11_2_025006 crossref_primary_10_3389_fnagi_2022_917629 crossref_primary_10_1016_j_parkreldis_2025_108009 crossref_primary_10_1111_cns_13916 crossref_primary_10_1096_fj_202100408RR crossref_primary_10_33549_physiolres_934929 crossref_primary_10_1016_j_jcyt_2021_09_013 crossref_primary_10_1177_01939459251365725 crossref_primary_10_3389_fnins_2022_1029473 crossref_primary_10_1021_jacs_3c09335 crossref_primary_10_3390_ijms242316787 crossref_primary_10_5535_arm_250067 crossref_primary_10_3389_fncel_2023_1166770 crossref_primary_10_3389_fspor_2024_1380864 crossref_primary_10_3389_fnmol_2024_1379889 crossref_primary_10_1080_17568919_2024_2444875 crossref_primary_10_3389_fnins_2024_1351718 crossref_primary_10_3390_jcm12154896 crossref_primary_10_1038_s41420_024_01912_9 crossref_primary_10_1371_journal_pone_0290317 crossref_primary_10_1186_s12964_025_02383_w crossref_primary_10_1016_j_expneurol_2025_115253 crossref_primary_10_1177_1073858420939034 crossref_primary_10_1038_s41598_023_29299_0 crossref_primary_10_3389_fimmu_2024_1454102 crossref_primary_10_1002_cbdv_202301509 crossref_primary_10_1016_j_molliq_2021_116105 crossref_primary_10_3389_fimmu_2022_948615 crossref_primary_10_1155_2022_7393557 crossref_primary_10_1177_1089313X241242632 crossref_primary_10_1083_jcb_202412055 crossref_primary_10_1016_j_ejphar_2025_177644 crossref_primary_10_3390_ijms21134718 crossref_primary_10_1016_j_nbd_2023_106224 crossref_primary_10_18261_ks_38_3_3 crossref_primary_10_3390_s22134975 crossref_primary_10_3390_ijms241210366 crossref_primary_10_3389_fmolb_2023_1155753 crossref_primary_10_1089_ars_2022_0079 crossref_primary_10_1007_s10517_024_06199_5 crossref_primary_10_1007_s12565_020_00538_y crossref_primary_10_1186_s41983_023_00679_7 crossref_primary_10_1016_j_arr_2025_102873 crossref_primary_10_1038_s41531_024_00799_8 crossref_primary_10_1186_s41983_021_00352_x crossref_primary_10_1080_07391102_2023_2193997 crossref_primary_10_3389_fncel_2020_00021 crossref_primary_10_3390_biomedicines10020371 crossref_primary_10_1007_s12640_023_00660_5 crossref_primary_10_1002_mdc3_70120 crossref_primary_10_3389_fnins_2022_971270 crossref_primary_10_61186_jrums_24_1_80 crossref_primary_10_1016_j_biopha_2022_112866 crossref_primary_10_3389_fneur_2021_660087 crossref_primary_10_1186_s41155_023_00259_x crossref_primary_10_1002_ptr_7220 crossref_primary_10_1016_j_neuroscience_2025_03_042 crossref_primary_10_3389_fnmol_2022_829291 crossref_primary_10_1016_j_compeleceng_2025_110644 crossref_primary_10_1111_cbdd_70082 crossref_primary_10_3390_antiox13040393 crossref_primary_10_1016_j_phymed_2023_154686 crossref_primary_10_3390_antiox14070819 crossref_primary_10_1002_pmrj_13166 crossref_primary_10_3390_ijms24043321 crossref_primary_10_1016_j_jbmt_2025_05_071 crossref_primary_10_3390_ijms241814304 crossref_primary_10_1002_mdc3_14206 crossref_primary_10_1038_s41392_023_01588_0 crossref_primary_10_3390_molecules28114264 crossref_primary_10_1016_j_prmcm_2023_100235 crossref_primary_10_1016_j_prdoa_2025_100392 crossref_primary_10_3233_NRE_220029 crossref_primary_10_3390_ijms23137086 crossref_primary_10_1177_15459683221095034 crossref_primary_10_1016_j_pneurobio_2025_102770 crossref_primary_10_1016_j_preteyeres_2024_101292 crossref_primary_10_3389_fneur_2021_661117 crossref_primary_10_1016_j_biomaterials_2025_123548 crossref_primary_10_3390_biomedicines13092070 crossref_primary_10_17116_jnevro202412404128 crossref_primary_10_1016_j_heliyon_2025_e41831 crossref_primary_10_1016_j_neulet_2022_136667 crossref_primary_10_1080_01616412_2022_2129768 crossref_primary_10_1080_02687038_2023_2219026 crossref_primary_10_1007_s11481_020_09955_2 crossref_primary_10_1111_nyas_14860 crossref_primary_10_1371_journal_pone_0276218 crossref_primary_10_2196_48175 crossref_primary_10_1109_JBHI_2023_3239780 crossref_primary_10_1136_jnnp_2021_326280 crossref_primary_10_3389_fnagi_2023_1187157 crossref_primary_10_3390_ijms22042038 crossref_primary_10_1155_2021_9923331 crossref_primary_10_1016_j_jelekin_2025_103023 crossref_primary_10_3389_fneur_2024_1407241 crossref_primary_10_1080_00207454_2023_2292958 crossref_primary_10_1134_S0006297924100092 crossref_primary_10_1007_s12035_021_02500_z crossref_primary_10_1080_00207454_2022_2079501 crossref_primary_10_3389_fneur_2025_1381500 crossref_primary_10_1007_s00109_023_02382_9 crossref_primary_10_1186_s12974_023_02842_6 crossref_primary_10_1016_j_mito_2022_02_003 crossref_primary_10_1002_ana_26187 crossref_primary_10_1016_j_bioorg_2023_106906 crossref_primary_10_3390_biom12121745 crossref_primary_10_1136_bmjopen_2023_080592 crossref_primary_10_1007_s10943_023_01950_0 crossref_primary_10_1007_s00234_024_03452_6 crossref_primary_10_23736_S0390_5616_25_06526_9 crossref_primary_10_3390_life15030492 crossref_primary_10_1016_j_mocell_2024_100173 crossref_primary_10_1007_s40263_020_00727_3 crossref_primary_10_1088_1361_6501_adc297 crossref_primary_10_3758_s13415_024_01211_x crossref_primary_10_1088_1741_2552_ad3eb6 crossref_primary_10_1016_j_jep_2023_116878 crossref_primary_10_4155_fmc_2023_0035 crossref_primary_10_3389_fnagi_2022_996217 crossref_primary_10_1002_hbm_26156 crossref_primary_10_3390_electronics9101695 crossref_primary_10_3390_ijms24109105 crossref_primary_10_1007_s12035_020_01931_4 crossref_primary_10_1016_j_heliyon_2023_e18045 crossref_primary_10_1016_j_ijbiomac_2024_135826 crossref_primary_10_1186_s12883_022_02600_w crossref_primary_10_3390_genes12050720 crossref_primary_10_3390_jcm11144236 crossref_primary_10_1038_s41531_024_00647_9 crossref_primary_10_1016_j_mad_2022_111686 crossref_primary_10_1016_j_heliyon_2024_e32877 crossref_primary_10_1016_j_ejmech_2025_117452 crossref_primary_10_1073_pnas_2208792120 crossref_primary_10_3390_biom13101444 crossref_primary_10_1007_s43440_024_00610_8 crossref_primary_10_1038_s41433_023_02438_7 crossref_primary_10_1016_j_heliyon_2024_e30452 crossref_primary_10_1016_j_pneurobio_2025_102734 crossref_primary_10_1007_s12035_023_03773_2 crossref_primary_10_3389_fcimb_2022_939085 crossref_primary_10_1007_s11030_024_10808_w crossref_primary_10_2147_JIR_S521744 crossref_primary_10_3389_fnins_2021_689723 crossref_primary_10_3390_app13084974 crossref_primary_10_1016_j_compbiomed_2024_107951 crossref_primary_10_1016_j_intimp_2025_114201 crossref_primary_10_1016_j_ijbiomac_2024_134962 crossref_primary_10_3389_fnagi_2021_793023 crossref_primary_10_1017_neu_2020_30 crossref_primary_10_1007_s12035_023_03372_1 crossref_primary_10_1016_j_bbr_2022_114204 crossref_primary_10_3389_fncom_2023_1218707 crossref_primary_10_1038_s12276_024_01202_5 crossref_primary_10_1212_WNL_0000000000209747 crossref_primary_10_1002_mc_23553 crossref_primary_10_1016_j_cbi_2022_110002 crossref_primary_10_1016_j_snb_2021_130892 crossref_primary_10_1007_s10967_023_08907_3 crossref_primary_10_1186_s12967_025_06354_0 crossref_primary_10_3389_fnagi_2022_990913 crossref_primary_10_3389_fneur_2023_1097251 crossref_primary_10_1016_j_clinbiomech_2024_106298 crossref_primary_10_1016_j_euroneuro_2021_01_021 crossref_primary_10_1016_j_mito_2022_01_006 crossref_primary_10_1155_2024_4530255 crossref_primary_10_1016_j_neuint_2024_105760 crossref_primary_10_1111_ejn_16541 crossref_primary_10_4103_abr_abr_148_20 crossref_primary_10_1080_1061186X_2024_2315468 crossref_primary_10_1007_s11042_024_18906_5 crossref_primary_10_1016_j_bcp_2023_115524 crossref_primary_10_1007_s12640_022_00619_y crossref_primary_10_1109_TNSRE_2023_3269569 crossref_primary_10_3892_etm_2022_11299 crossref_primary_10_1016_j_ejps_2021_106056 crossref_primary_10_1007_s11065_024_09656_0 crossref_primary_10_3389_fphar_2024_1487474 crossref_primary_10_3390_ijms25042286 crossref_primary_10_1016_j_brainresbull_2024_111024 crossref_primary_10_1111_jnc_14968 crossref_primary_10_1111_ene_15654 crossref_primary_10_3390_nu14030676 crossref_primary_10_3389_fneur_2023_1260445 crossref_primary_10_1016_j_jneumeth_2022_109687 crossref_primary_10_1016_j_bbr_2022_113774 crossref_primary_10_3389_fgene_2024_1496683 crossref_primary_10_1080_10833196_2021_1908728 crossref_primary_10_1111_cns_14241 crossref_primary_10_3390_jcm9030736 crossref_primary_10_3390_bioengineering10010051 crossref_primary_10_3390_biology13121056 crossref_primary_10_1016_j_abb_2023_109698 crossref_primary_10_1007_s00415_025_12962_z crossref_primary_10_1016_j_intimp_2023_110109 crossref_primary_10_3390_brainsci14111147 crossref_primary_10_3390_app142411781 crossref_primary_10_1007_s12640_021_00460_9 crossref_primary_10_3389_fnagi_2025_1612544 crossref_primary_10_1038_s41531_022_00333_8 crossref_primary_10_14814_phy2_15772 crossref_primary_10_1111_cns_14025 crossref_primary_10_1016_j_phymed_2022_154582 crossref_primary_10_1016_j_jad_2022_08_026 crossref_primary_10_3390_s24185957 crossref_primary_10_1016_j_cpha_2024_08_003 crossref_primary_10_1007_s10072_022_06347_7 crossref_primary_10_1007_s11136_024_03616_0 crossref_primary_10_3390_cells11020198 crossref_primary_10_1002_advs_202307971 crossref_primary_10_3389_fpsyg_2024_1374924 crossref_primary_10_1111_jsr_70193 crossref_primary_10_3390_ijms24054628 crossref_primary_10_1002_med_22035 crossref_primary_10_1016_j_jchemneu_2022_102188 crossref_primary_10_1177_0271678X231164337 crossref_primary_10_3390_ph16101424 crossref_primary_10_1080_1028415X_2023_2243089 crossref_primary_10_3390_molecules29204799 crossref_primary_10_1007_s12035_024_04253_x crossref_primary_10_1016_j_jddst_2020_101790 crossref_primary_10_1155_2020_3807476 crossref_primary_10_1007_s11042_024_20276_x crossref_primary_10_1155_2022_7389658 crossref_primary_10_3389_fneur_2021_720958 crossref_primary_10_3390_bios11090296 crossref_primary_10_1080_17460441_2020_1767580 crossref_primary_10_3390_md23080310 crossref_primary_10_1109_TNSRE_2025_3574999 crossref_primary_10_1016_j_jocn_2022_04_015 crossref_primary_10_1038_s41598_024_61844_3 crossref_primary_10_1152_japplphysiol_00219_2024 crossref_primary_10_3389_fnagi_2023_1188855 crossref_primary_10_3389_fcell_2023_1214450 crossref_primary_10_1007_s42979_022_01018_y crossref_primary_10_1039_D0BM02164D crossref_primary_10_3390_ijms22084052 crossref_primary_10_1002_mds_29326 crossref_primary_10_1016_j_neurobiolaging_2021_06_011 crossref_primary_10_1155_2021_7479423 crossref_primary_10_3390_brainsci12101343 crossref_primary_10_3390_biomedicines10092261 crossref_primary_10_1097_MD_0000000000033714 crossref_primary_10_1016_j_neubiorev_2024_105999 crossref_primary_10_3390_pharmaceutics17030280 crossref_primary_10_1007_s11011_025_01568_z crossref_primary_10_1186_s12912_024_01837_9 crossref_primary_10_4103_cjop_CJOP_D_23_00107 crossref_primary_10_1007_s40142_024_00210_1 crossref_primary_10_1186_s12883_023_03380_7 crossref_primary_10_1038_s41598_024_74526_x crossref_primary_10_1016_j_prp_2023_155023 crossref_primary_10_1007_s10072_025_08114_w crossref_primary_10_3389_fneur_2020_01044 crossref_primary_10_1038_s41531_025_00931_2 crossref_primary_10_1186_s40035_025_00481_w crossref_primary_10_1016_j_jcyt_2025_04_058 crossref_primary_10_3390_biomedicines10112746 crossref_primary_10_1093_brain_awaf132 crossref_primary_10_1155_2022_2233906 crossref_primary_10_1007_s10143_024_02611_w crossref_primary_10_1002_brb3_70169 crossref_primary_10_31083_j_jin2306109 crossref_primary_10_1007_s12035_023_03392_x crossref_primary_10_3389_fnins_2022_900338 crossref_primary_10_3390_biomedicines10112986 crossref_primary_10_3390_molecules27217468 crossref_primary_10_2174_0929867327666200903115138 crossref_primary_10_1016_j_jaad_2024_02_060 crossref_primary_10_1016_j_obmed_2023_100500 crossref_primary_10_3389_fnagi_2021_760781 crossref_primary_10_1016_j_expneurol_2024_114997 crossref_primary_10_3389_fneur_2023_1257064 crossref_primary_10_1002_jbt_70021 crossref_primary_10_1038_s41746_024_01175_9 crossref_primary_10_1016_j_biopha_2025_118158 crossref_primary_10_3390_ijms25179489 crossref_primary_10_1016_j_pnpbp_2024_111116 crossref_primary_10_1002_biof_1891 crossref_primary_10_1111_gbb_12896 crossref_primary_10_1016_j_taap_2023_116678 crossref_primary_10_3389_fphar_2025_1593191 crossref_primary_10_1038_s41598_022_25180_8 crossref_primary_10_3390_antiox13091138 crossref_primary_10_3389_fpsyt_2024_1377403 crossref_primary_10_1007_s11332_024_01197_6 crossref_primary_10_3390_molecules27217207 crossref_primary_10_1038_s41598_024_78132_9 crossref_primary_10_1016_j_neurom_2022_10_047 crossref_primary_10_1016_j_arr_2021_101391 crossref_primary_10_5014_ajot_2023_050233 crossref_primary_10_1073_pnas_2313465121 crossref_primary_10_1080_17460441_2023_2221024 crossref_primary_10_3233_JPD_212611 crossref_primary_10_1016_j_jconrel_2025_113641 crossref_primary_10_1186_s41983_024_00827_7 crossref_primary_10_1038_s41531_022_00377_w crossref_primary_10_3389_fphar_2022_898797 crossref_primary_10_3389_fcell_2021_635104 crossref_primary_10_1007_s10072_021_05854_3 crossref_primary_10_1016_j_nexres_2025_100473 crossref_primary_10_1016_j_parkreldis_2024_106011 crossref_primary_10_1007_s12031_023_02128_9 crossref_primary_10_1109_TNSRE_2024_3449316 crossref_primary_10_3390_antiox9100928 crossref_primary_10_6061_clinics_2021_e3266 crossref_primary_10_3390_antiox13020218 crossref_primary_10_1186_s12883_022_03027_z crossref_primary_10_3389_fcell_2022_798826 crossref_primary_10_3389_fneur_2024_1403105 crossref_primary_10_1016_j_ejphar_2024_176766 crossref_primary_10_3390_ijms24108614 crossref_primary_10_1016_j_nutres_2023_10_004 crossref_primary_10_1080_00207454_2022_2107517 crossref_primary_10_3389_fnins_2021_621173 crossref_primary_10_1016_j_ejmech_2023_115475 crossref_primary_10_3389_fphys_2022_1031803 crossref_primary_10_1002_mds_29596 crossref_primary_10_1016_j_phrs_2023_106787 crossref_primary_10_32604_biocell_2024_053597 crossref_primary_10_1016_j_neuint_2022_105356 crossref_primary_10_3390_s25082405 crossref_primary_10_3389_fphar_2021_675725 crossref_primary_10_3897_pharmacia_72_e164727 crossref_primary_10_1007_s12247_022_09625_1 crossref_primary_10_1186_s12883_025_04167_8 crossref_primary_10_1080_07853890_2023_2251145 crossref_primary_10_1515_revneuro_2023_0026 crossref_primary_10_1016_j_arr_2021_101347 crossref_primary_10_1007_s00415_024_12863_7 crossref_primary_10_3390_ijms232012105 crossref_primary_10_1016_j_arr_2021_101359 crossref_primary_10_1186_s12987_023_00490_9 crossref_primary_10_3390_ijms25126711 crossref_primary_10_1080_02648725_2023_2200333 crossref_primary_10_1016_j_arr_2022_101817 crossref_primary_10_1007_s00401_023_02632_7 crossref_primary_10_1124_pharmrev_120_000281 crossref_primary_10_1186_s13024_022_00555_7 crossref_primary_10_1007_s12035_024_04392_1 crossref_primary_10_3390_s23229149 crossref_primary_10_1016_j_compbiomed_2024_108462 crossref_primary_10_1038_s41531_025_00947_8 crossref_primary_10_1016_j_heliyon_2024_e34120 crossref_primary_10_1097_MD_0000000000031002 crossref_primary_10_3390_antiox11081511 crossref_primary_10_1016_j_neulet_2023_137575 crossref_primary_10_1177_02841851221094967 crossref_primary_10_1007_s10044_025_01514_w crossref_primary_10_3390_cells10030656 crossref_primary_10_3389_fphar_2024_1422080 crossref_primary_10_1111_cns_70434 crossref_primary_10_1002_jmri_29056 crossref_primary_10_1148_rg_230133 crossref_primary_10_1007_s12149_025_02053_4 crossref_primary_10_23736_S0026_4806_25_09695_8 crossref_primary_10_3389_fgene_2021_744299 crossref_primary_10_1016_j_eswa_2023_120541 crossref_primary_10_3390_biomedicines11092524 crossref_primary_10_1155_2023_9412776 crossref_primary_10_3389_fneur_2022_971252 crossref_primary_10_1519_JPT_0000000000000373 crossref_primary_10_1038_s41380_022_01796_0 crossref_primary_10_1111_cns_70424 crossref_primary_10_1016_j_pnpbp_2023_110903 crossref_primary_10_1093_bib_bbac405 crossref_primary_10_3390_ijms241813929 crossref_primary_10_3390_brainsci13050790 crossref_primary_10_3390_cells11020268 crossref_primary_10_3390_ijms22168649 crossref_primary_10_1007_s15005_022_2446_6 crossref_primary_10_1016_j_sjbs_2023_103656 crossref_primary_10_3389_fnagi_2024_1358141 crossref_primary_10_1016_j_nutos_2024_05_012 crossref_primary_10_1134_S1819712424020090 crossref_primary_10_1038_s44286_025_00219_5 crossref_primary_10_1016_j_bbr_2025_115775 crossref_primary_10_3390_ijms24065842 crossref_primary_10_1016_j_brainres_2024_149414 crossref_primary_10_1016_j_arr_2021_101543 crossref_primary_10_1016_j_cca_2023_117322 crossref_primary_10_3390_ijms23094718 crossref_primary_10_1002_ca_23792 crossref_primary_10_3390_molecules29163943 crossref_primary_10_3390_electronics12183753 crossref_primary_10_1134_S0022093025020085 crossref_primary_10_11124_JBIES_24_00183 crossref_primary_10_1016_j_bbi_2022_10_023 crossref_primary_10_1002_ima_22948 crossref_primary_10_3390_ijms26136138 crossref_primary_10_1177_01939459251341814 crossref_primary_10_1177_09727531211046362 crossref_primary_10_3390_ijms21165724 crossref_primary_10_1016_j_arr_2021_101554 crossref_primary_10_1007_s10534_023_00530_9 crossref_primary_10_1016_j_rh_2022_07_004 crossref_primary_10_2196_62822 crossref_primary_10_3389_fbioe_2022_983488 crossref_primary_10_3390_medicina59050935 crossref_primary_10_3389_fnagi_2022_1077738 crossref_primary_10_1038_s41531_024_00863_3 crossref_primary_10_1016_j_clinsp_2021_100001 crossref_primary_10_3389_fnagi_2022_938408 crossref_primary_10_1186_s12877_024_04845_1 crossref_primary_10_1016_j_neuroscience_2021_10_025 crossref_primary_10_24884_1607_4181_2025_32_1_52_58 crossref_primary_10_3390_nu12113523 crossref_primary_10_1177_15459683241300456 crossref_primary_10_1007_s11845_024_03673_x crossref_primary_10_1186_s13024_023_00639_y crossref_primary_10_4274_tjps_galenos_2021_95226 crossref_primary_10_1007_s11571_023_10048_y crossref_primary_10_3389_fneur_2021_652375 crossref_primary_10_3390_cancers16152680 crossref_primary_10_1088_2632_072X_adf58a crossref_primary_10_1038_s41401_023_01141_3 crossref_primary_10_3390_antiox9121203 crossref_primary_10_3390_ijms25168971 crossref_primary_10_3390_app12030949 crossref_primary_10_3390_cells9040846 crossref_primary_10_1002_brb3_2628 crossref_primary_10_1159_000546733 crossref_primary_10_3390_cells9040841 crossref_primary_10_1002_cbdv_202300979 crossref_primary_10_3233_JPD_240014 crossref_primary_10_1016_j_humov_2024_103201 crossref_primary_10_1016_j_jddst_2023_105067 crossref_primary_10_3390_diagnostics12123000 crossref_primary_10_3390_antiox12030673 crossref_primary_10_3389_fnagi_2024_1399098 crossref_primary_10_3389_fneur_2023_1208213 crossref_primary_10_5334_tohm_712 crossref_primary_10_54044_RAMI_2023_01_08 crossref_primary_10_1016_j_brs_2025_03_012 crossref_primary_10_1007_s11055_023_01549_8 crossref_primary_10_1002_mdc3_70206 crossref_primary_10_1016_j_niox_2023_04_003 crossref_primary_10_17816_MAJ630023 crossref_primary_10_1093_jb_mvad100 crossref_primary_10_2147_DMSO_S359856 crossref_primary_10_4103_NRR_NRR_D_24_00994 crossref_primary_10_1038_s41420_023_01333_0 crossref_primary_10_3389_fnagi_2023_1191378 crossref_primary_10_1016_j_biopha_2022_113637 crossref_primary_10_1016_j_bcp_2025_117301 crossref_primary_10_1016_j_ijbiomac_2025_145303 crossref_primary_10_1007_s42399_025_01838_y crossref_primary_10_1007_s12035_024_04611_9 crossref_primary_10_3389_fphar_2023_1088957 crossref_primary_10_1007_s11033_024_09484_8 crossref_primary_10_1016_j_nutos_2023_09_005 crossref_primary_10_1007_s11356_021_15955_3 crossref_primary_10_1177_00315125211065312 crossref_primary_10_18863_pgy_1374234 crossref_primary_10_1002_jemt_24442 crossref_primary_10_3390_healthcare13101214 crossref_primary_10_1089_jicm_2023_0026 crossref_primary_10_57264_cer_2024_0186 crossref_primary_10_1002_jcb_30624 crossref_primary_10_3389_fnut_2022_836500 crossref_primary_10_1007_s10072_021_05754_6 crossref_primary_10_1016_j_nbd_2020_104979 crossref_primary_10_3390_ijms25137183 crossref_primary_10_3389_fneur_2021_666737 crossref_primary_10_3389_fnagi_2022_936027 crossref_primary_10_1186_s13062_021_00303_9 crossref_primary_10_1016_j_ecoenv_2024_116841 crossref_primary_10_1016_j_neuint_2024_105700 crossref_primary_10_3390_cells13040340 crossref_primary_10_1016_j_bcp_2024_116174 crossref_primary_10_3390_ijms232213775 crossref_primary_10_3390_life11111126 crossref_primary_10_1186_s40580_024_00426_5 crossref_primary_10_1111_ane_13652 crossref_primary_10_21020_husbfd_1562976 crossref_primary_10_1002_jbt_22659 crossref_primary_10_1016_j_bbii_2023_100038 crossref_primary_10_1007_s10072_022_06440_x crossref_primary_10_1007_s12031_022_02053_3 crossref_primary_10_1080_1028415X_2023_2296164 crossref_primary_10_1016_j_jaging_2020_100910 crossref_primary_10_1002_brb3_70721 crossref_primary_10_3233_JPD_202190 crossref_primary_10_3389_fneur_2023_1172320 crossref_primary_10_1016_j_compbiomed_2023_107705 crossref_primary_10_3389_fnagi_2024_1333289 crossref_primary_10_3389_fneur_2024_1422672 crossref_primary_10_1007_s11011_023_01180_z crossref_primary_10_1038_s41598_024_81787_z crossref_primary_10_1186_s12938_023_01167_y crossref_primary_10_20538_1682_0363_2022_4_105_113 crossref_primary_10_3390_brainsci14060620 crossref_primary_10_1016_j_jff_2025_106717 crossref_primary_10_1111_1440_1681_13691 crossref_primary_10_3389_fpsyg_2025_1542405 crossref_primary_10_3390_brainsci11081100 crossref_primary_10_3390_diseases11030115 crossref_primary_10_1136_jnnp_2025_336045 crossref_primary_10_1080_17435889_2025_2460228 crossref_primary_10_1038_s41531_024_00645_x crossref_primary_10_1038_s41598_024_57152_5 crossref_primary_10_3390_biom13111658 crossref_primary_10_3389_fnagi_2023_1204149 crossref_primary_10_1016_j_ejps_2023_106491 crossref_primary_10_1186_s13578_023_01049_9 crossref_primary_10_1002_med_21939 crossref_primary_10_17816_MAJ624867 crossref_primary_10_3390_brainsci14070695 crossref_primary_10_1002_sen2_70012 crossref_primary_10_3389_fneur_2025_1657824 crossref_primary_10_3389_fgene_2021_757601 crossref_primary_10_3390_ijms26073275 crossref_primary_10_1016_j_expneurol_2023_114370 crossref_primary_10_1016_j_phymed_2022_154044 crossref_primary_10_1007_s13346_022_01285_5 crossref_primary_10_1111_acel_13834 crossref_primary_10_1155_2022_4665530 crossref_primary_10_1186_s12883_025_04128_1 crossref_primary_10_1177_15459683231207359 crossref_primary_10_3390_s22030824 crossref_primary_10_1080_21679169_2025_2476457 crossref_primary_10_1007_s00604_023_05783_2 crossref_primary_10_1136_bmjopen_2023_071726 crossref_primary_10_3390_jpm14060588 crossref_primary_10_1177_07334648251328441 crossref_primary_10_4103_2221_1691_343387 crossref_primary_10_1016_j_nicl_2023_103405 crossref_primary_10_1016_j_npep_2025_102534 crossref_primary_10_1016_j_cnsns_2023_107142 crossref_primary_10_1093_nsr_nwae079 crossref_primary_10_3389_fnagi_2022_885500 crossref_primary_10_47924_neurotarget2023461 crossref_primary_10_1016_j_neuroscience_2025_07_003 crossref_primary_10_1007_s10072_023_06926_2 crossref_primary_10_1016_j_freeradbiomed_2021_08_230 crossref_primary_10_1038_s41531_023_00607_9 crossref_primary_10_3389_fneur_2023_1326640 crossref_primary_10_1007_s00441_020_03214_9 crossref_primary_10_1007_s11011_023_01222_6 crossref_primary_10_1016_j_amjmed_2022_04_029 crossref_primary_10_3390_nu14224833 crossref_primary_10_3390_diagnostics10090684 crossref_primary_10_1080_15287394_2025_2470847 crossref_primary_10_3390_pharmaceutics14112425 crossref_primary_10_1016_j_mehy_2020_109722 crossref_primary_10_3389_fnmol_2023_1209703 crossref_primary_10_1111_jjns_12418 crossref_primary_10_3390_cells11081261 crossref_primary_10_1016_j_nrleng_2025_06_001 crossref_primary_10_3389_fneur_2023_1324216 crossref_primary_10_1186_s13690_024_01445_8 crossref_primary_10_1016_j_neuroscience_2025_08_018 crossref_primary_10_3390_nu14061220 crossref_primary_10_1097_MD_0000000000040786 crossref_primary_10_3390_app151810162 crossref_primary_10_1002_jbt_70322 crossref_primary_10_3892_mmr_2021_12374 crossref_primary_10_1016_j_clineuro_2023_107595 crossref_primary_10_1111_cns_14167 crossref_primary_10_1177_02841851211055401 crossref_primary_10_1038_s41531_021_00198_3 crossref_primary_10_36290_far_2024_009 crossref_primary_10_1016_j_talanta_2024_127247 crossref_primary_10_1038_s41419_020_03228_9 crossref_primary_10_1016_j_cbpa_2021_05_007 crossref_primary_10_3390_ijms25137102 crossref_primary_10_1016_j_jics_2025_101790 crossref_primary_10_1016_j_ejphar_2025_177273 crossref_primary_10_1016_j_bbih_2025_100948 crossref_primary_10_3389_fimmu_2025_1654664 crossref_primary_10_1016_j_biopha_2023_115021 crossref_primary_10_1155_2022_8683877 crossref_primary_10_1080_01616412_2022_2162219 crossref_primary_10_1146_annurev_biochem_071322_021330 crossref_primary_10_3390_cells10020283 crossref_primary_10_1007_s40520_024_02922_4 crossref_primary_10_1080_15287394_2023_2261120 crossref_primary_10_2147_EB_S516393 crossref_primary_10_3390_ijms23084134 crossref_primary_10_1016_j_cellsig_2022_110386 crossref_primary_10_3390_jcm13144130 crossref_primary_10_1007_s12640_023_00637_4 crossref_primary_10_1016_j_intimp_2022_108694 crossref_primary_10_1007_s12281_024_00493_5 crossref_primary_10_1016_j_jbc_2024_108051 crossref_primary_10_1016_j_isci_2023_107787 crossref_primary_10_3390_ijms232214018 crossref_primary_10_3390_cells10123547 crossref_primary_10_3390_ijms25084337 crossref_primary_10_3389_fnmol_2022_1071731 crossref_primary_10_3390_ijms221910240 crossref_primary_10_1016_j_bbrc_2022_07_058 crossref_primary_10_3390_nano12132267 crossref_primary_10_1186_s12883_025_04161_0 crossref_primary_10_1080_09638288_2024_2421440 crossref_primary_10_31083_j_jin2302037 crossref_primary_10_1038_s41746_024_01217_2 crossref_primary_10_1016_j_compbiomed_2025_109767 crossref_primary_10_1590_rbce_47_e20240071 crossref_primary_10_3390_ai6040068 crossref_primary_10_1016_j_neuropharm_2022_108964 crossref_primary_10_1186_s12984_024_01411_z crossref_primary_10_1371_journal_pone_0322009 crossref_primary_10_1111_ejn_16669 crossref_primary_10_1109_JBHI_2025_3532695 crossref_primary_10_1016_j_npg_2025_04_002 crossref_primary_10_3390_biomedicines11030919 crossref_primary_10_1016_j_clinsp_2022_100085 crossref_primary_10_1080_17582024_2025_2520707 crossref_primary_10_3390_ijms232214276 crossref_primary_10_1016_j_nrleng_2023_04_008 crossref_primary_10_1038_s41598_023_50546_x crossref_primary_10_1177_10538135241308786 crossref_primary_10_1080_07853890_2025_2452353 crossref_primary_10_3233_THC_235010 crossref_primary_10_1016_j_bcp_2025_117195 crossref_primary_10_3389_fnagi_2024_1417938 crossref_primary_10_3390_ijms222112087 crossref_primary_10_1080_1028415X_2022_2161129 crossref_primary_10_3389_fncom_2024_1386841 crossref_primary_10_7759_cureus_79409 crossref_primary_10_3390_antiox10050794 crossref_primary_10_1002_mdc3_13630 crossref_primary_10_1016_j_euroneuro_2021_10_799 crossref_primary_10_1080_1028415X_2023_2180865 crossref_primary_10_1186_s13024_025_00816_1 crossref_primary_10_1186_s12951_023_02004_z crossref_primary_10_3390_biom11081101 crossref_primary_10_1007_s12011_023_03748_3 crossref_primary_10_3390_ijms23084176 crossref_primary_10_1016_j_scispo_2025_07_005 crossref_primary_10_3390_nu13020543 crossref_primary_10_1016_j_fct_2021_112752 crossref_primary_10_1142_S0192415X23500167 crossref_primary_10_31083_j_jin2304086 crossref_primary_10_1016_j_jff_2023_105856 crossref_primary_10_1016_j_nbd_2022_105777 crossref_primary_10_3390_cells12070992 crossref_primary_10_1007_s13167_021_00237_2 crossref_primary_10_1016_j_brainres_2023_148320 crossref_primary_10_1007_s11055_024_01685_9 crossref_primary_10_1007_s12035_023_03238_6 crossref_primary_10_3233_BMR_230259 crossref_primary_10_3390_ijerph18179410 crossref_primary_10_3390_diagnostics12082003 crossref_primary_10_3390_ijms252312842 crossref_primary_10_1093_brain_awac171 crossref_primary_10_3390_bios13010072 crossref_primary_10_1097_MD_0000000000033619 crossref_primary_10_1016_j_bmc_2022_116818 crossref_primary_10_2147_JPRLS_S306244 crossref_primary_10_1016_j_neuropharm_2020_108173 crossref_primary_10_1186_s12974_024_03296_0 crossref_primary_10_5014_ajot_2021_042101 crossref_primary_10_3390_ijms22126223 crossref_primary_10_3390_s21217230 crossref_primary_10_1097_NPT_0000000000000440 crossref_primary_10_1152_jn_00055_2023 crossref_primary_10_1007_s40120_023_00574_6 crossref_primary_10_1002_mdc3_13868 crossref_primary_10_3390_nu15020386 crossref_primary_10_1016_j_jamda_2023_04_004 crossref_primary_10_1016_j_jtbi_2021_110979 crossref_primary_10_3390_ejihpe14050085 crossref_primary_10_3390_cells12091270 crossref_primary_10_3390_ijms26020542 crossref_primary_10_1016_j_jchemneu_2021_101965 crossref_primary_10_3390_pharmaceutics14102252 crossref_primary_10_3389_fpsyg_2024_1356553 crossref_primary_10_1139_cjpp_2021_0013 crossref_primary_10_21733_ibad_1700404 crossref_primary_10_3390_ijms25158447 crossref_primary_10_1002_glia_70055 crossref_primary_10_3390_ijms24076338 crossref_primary_10_3389_fdgth_2024_1435693 crossref_primary_10_3389_fnagi_2023_1149143 crossref_primary_10_3758_s13415_023_01106_3 crossref_primary_10_1016_j_clinbiomech_2021_105488 crossref_primary_10_3390_ijms24021685 crossref_primary_10_1007_s12272_025_01538_0 crossref_primary_10_1016_j_ejmech_2022_114692 crossref_primary_10_1111_ene_70118 crossref_primary_10_1111_pcn_13759 crossref_primary_10_1007_s12640_021_00450_x crossref_primary_10_1038_s41598_022_06539_3 crossref_primary_10_3390_cells11213445 crossref_primary_10_1002_mds_29432 crossref_primary_10_1016_j_dscb_2024_100158 crossref_primary_10_1097_MD_0000000000041218 crossref_primary_10_1136_jnnp_2019_322338 crossref_primary_10_1016_j_parkreldis_2023_105386 crossref_primary_10_3389_fneur_2021_627999 crossref_primary_10_3389_fnins_2022_874349 crossref_primary_10_1016_j_jneuroim_2021_577758 crossref_primary_10_1002_brb3_70288 crossref_primary_10_3389_fnagi_2022_1023574 crossref_primary_10_3390_brainsci13020201 crossref_primary_10_1177_1073858421990000 crossref_primary_10_3233_THC_240821 crossref_primary_10_1016_j_arcmed_2024_102988 crossref_primary_10_1186_s13765_022_00710_0 crossref_primary_10_1016_j_biopha_2023_115408 crossref_primary_10_1016_j_ijbiomac_2025_141814 crossref_primary_10_1111_hsc_13970 crossref_primary_10_3389_fnagi_2025_1602426 crossref_primary_10_1038_s41531_024_00715_0 crossref_primary_10_3233_JPD_202503 crossref_primary_10_3390_biomedicines10040760 crossref_primary_10_1111_jnc_15516 crossref_primary_10_3390_ijms25158425 crossref_primary_10_3390_ijms24076313 crossref_primary_10_1016_j_gaitpost_2024_06_001 crossref_primary_10_1016_j_neuroimage_2022_119454 crossref_primary_10_3389_fnmol_2022_949095 crossref_primary_10_1186_s40035_021_00239_0 crossref_primary_10_3389_fneur_2022_995747 crossref_primary_10_1038_s41467_025_62895_4 crossref_primary_10_1007_s10008_025_06192_6 crossref_primary_10_1016_j_engmic_2025_100222 crossref_primary_10_3390_ijms23063033 crossref_primary_10_3389_fpubh_2025_1557338 crossref_primary_10_3390_s21217034 crossref_primary_10_4103_2045_9912_385945 crossref_primary_10_1111_jnc_15524 crossref_primary_10_3389_fneur_2022_885179 crossref_primary_10_1002_brx2_70011 |
| Cites_doi | 10.1016/j.neuint.2018.08.005 10.1002/mds.20300 10.1016/j.parkreldis.2017.06.006 10.1111/ane.12107 10.1038/nrn.2017.62 10.1002/mds.25742 10.1080/15548627.2015.1067364 10.1212/WNL.0000000000002510 10.1056/NEJM198801073180115 10.1016/S0140-6736(17)31585-4 10.1038/nrd.2018.136 10.3233/JPD-161020 10.1002/mds.26121 10.1002/1531-8257(199907)14:4<572::AID-MDS1005>3.0.CO;2-C 10.1002/mds.26481 10.1016/S1474-4422(15)00144-1 10.1111/ene.12022 10.1002/mds.26219 10.1002/mds.27670 10.3233/JAD-2004-6412 10.1185/03007995.2011.560146 10.1056/NEJM199504273321702 10.1002/mds.23659 10.1136/jnnp.2006.100107 10.1111/j.1532-5415.2000.tb06891.x 10.1007/s11910-017-0738-x 10.1056/NEJMoa060281 10.1016/j.parkreldis.2014.05.011 10.1212/WNL.0b013e318248e520 10.1002/mds.25076 10.1212/WNL.43.11.2227 10.1016/S1474-4422(18)30179-0 10.1001/jamaneurol.2014.131 10.1016/bs.pbr.2017.02.008 10.1001/jama.2015.120 10.1016/S1474-4422(06)70521-X 10.1523/JNEUROSCI.1091-10.2010 10.1371/journal.pone.0012122 10.1002/mds.23829 10.1002/mds.27802 10.1038/nn.3361 10.1126/science.1096284 10.1073/pnas.1112368109 10.1212/01.wnl.0000215250.82576.87 10.1002/ana.410390107 10.1136/jnnp-2014-308764 10.1371/journal.pone.0151841 10.1002/mds.26697 10.1126/science.276.5321.2045 10.1016/S0197-4580(02)00065-9 10.1097/WCO.0000000000000349 10.1002/mds.25364 10.1007/s12035-012-8280-y 10.1001/jamaneurol.2016.4467 10.1016/j.cell.2016.11.018 10.1111/ane.12201 10.1111/ene.13412 10.1212/WNL.0b013e31824e8f0d 10.1186/s13024-017-0154-3 10.1016/j.yfrne.2014.02.002 10.1016/S0140-6736(15)00462-6 10.1016/j.parkreldis.2015.08.030 10.1016/0140-6736(90)91006-V 10.21037/atm.2019.02.10 10.1056/NEJMoa1900907 10.1177/0963689717735411 10.1016/S0002-9440(10)64553-1 10.1002/mds.27131 10.1016/j.jns.2016.12.060 10.1016/j.ncl.2014.09.012 10.1074/jbc.M208641200 10.1038/nrneurol.2015.197 10.1038/ng1769 10.1056/NEJMoa1205158 10.1016/j.ncl.2016.06.012 10.1093/brain/awz023 10.1016/j.parkreldis.2006.05.033 10.1371/journal.pone.0152564 10.1212/WNL.48.5.1277 10.1038/nrdp.2015.5 10.1007/s40263-015-0249-8 10.1177/1073858415581986 10.1038/nrneurol.2016.14 10.1212/WNL.0000000000004003 10.1016/S0140-6736(89)92366-0 10.1002/mds.25799 10.1038/s41598-017-01402-2 10.1002/mds.25383 10.1212/WNL.40.10.1529 10.1155/2015/697404 10.1002/mds.24996 10.1002/ana.10113 10.1002/biof.159 10.1001/archneur.61.4.561 10.1126/science.aaf3934 10.1002/ana.67 10.1007/s40265-014-0343-0 10.1002/mds.26424 10.1212/WNL.90.15_supplement.P2.039 10.1002/mds.20104 10.1212/WNL.60.1.69 10.1111/j.1468-1331.2011.03399.x 10.1016/j.euroneuro.2005.04.007 10.1177/1073858417748875 10.1016/S0140-6736(88)90950-6 10.1523/JNEUROSCI.2617-07.2007 10.1016/j.parkreldis.2013.01.009 10.1038/ng1884 10.1212/01.wnl.0000279518.10072.df 10.1126/science.6823561 10.1212/WNL.0b013e3181d5a4a3 10.1038/33416 10.1126/science.1077209 10.1002/ana.410440708 10.1517/13543784.2014.869209 10.1002/mds.21007 10.1016/j.nbd.2017.04.004 10.1002/mds.27121 |
| ContentType | Journal Article |
| Copyright | 2019 European Academy of Neurology 2019 European Academy of Neurology. Copyright © 2020 European Academy of Neurology |
| Copyright_xml | – notice: 2019 European Academy of Neurology – notice: 2019 European Academy of Neurology. – notice: Copyright © 2020 European Academy of Neurology |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7TK 7U7 C1K K9. 7X8 |
| DOI | 10.1111/ene.14108 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Neurosciences Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Toxicology Abstracts Neurosciences Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic ProQuest Health & Medical Complete (Alumni) MEDLINE CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1468-1331 |
| EndPage | 42 |
| ExternalDocumentID | 31631455 10_1111_ene_14108 ENE14108 |
| Genre | reviewArticle Journal Article Review |
| GeographicLocations | Europe |
| GeographicLocations_xml | – name: Europe |
| GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 169 1OB 1OC 24P 29G 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 702 7PT 7X7 8-0 8-1 8-3 8-4 8-5 8FI 8FJ 8UM 930 A01 A03 AAESR AAEVG AAHHS AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABIVO ABJNI ABPVW ABUWG ABXGK ACAHQ ACBWZ ACCFJ ACCMX ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADPDF ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFGKR AFKRA AFPWT AFRAH AFWVQ AFZJQ AHMBA AIACR AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BENPR BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG CCPQU COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EJD EMOBN ESX EX3 F00 F5P FEDTE FUBAC FYBCS FYUFA G-S G.N GODZA H.X HF~ HMCUK HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD OVEED P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 R.K RIG RIWAO RJQFR ROL RPM RX1 SAMSI SUPJJ TEORI UB1 UKHRP W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WVDHM WXI WXSBR XG1 YFH ZZTAW ~IA ~WT AAMMB AAYXX AEFGJ AGQPQ AGXDD AIDQK AIDYY AIQQE CITATION GROUPED_DOAJ O8X PHGZM WIN CGR CUY CVF ECM EIF NPM 7TK 7U7 C1K K9. 7X8 |
| ID | FETCH-LOGICAL-c4198-92d0887422ba588084fb871845b0e78521f655e11b984e4f8ca306a63d3242503 |
| IEDL.DBID | WIN |
| ISICitedReferencesCount | 804 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000498644200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1351-5101 1468-1331 |
| IngestDate | Fri Sep 05 13:09:58 EDT 2025 Sat Nov 29 14:33:18 EST 2025 Wed Feb 19 02:29:00 EST 2025 Tue Nov 18 22:24:37 EST 2025 Sat Nov 29 05:12:45 EST 2025 Wed Jan 22 16:41:02 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | treatment clinical genetics pathophysiology Parkinson disease neurodegeneration movement disorders |
| Language | English |
| License | 2019 European Academy of Neurology. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4198-92d0887422ba588084fb871845b0e78521f655e11b984e4f8ca306a63d3242503 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| PMID | 31631455 |
| PQID | 2322135403 |
| PQPubID | 1066358 |
| PageCount | 16 |
| ParticipantIDs | proquest_miscellaneous_2307399479 proquest_journals_2322135403 pubmed_primary_31631455 crossref_primary_10_1111_ene_14108 crossref_citationtrail_10_1111_ene_14108 wiley_primary_10_1111_ene_14108_ENE14108 |
| PublicationCentury | 2000 |
| PublicationDate | January 2020 |
| PublicationDateYYYYMMDD | 2020-01-01 |
| PublicationDate_xml | – month: 01 year: 2020 text: January 2020 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Oxford |
| PublicationTitle | European journal of neurology |
| PublicationTitleAlternate | Eur J Neurol |
| PublicationYear | 2020 |
| Publisher | John Wiley & Sons, Inc |
| Publisher_xml | – name: John Wiley & Sons, Inc |
| References | 1997; 48 2006; 38 2015; 75 2017; 88 2015; 386 2013; 368 1997; 276 2013; 128 2016; 31 2017; 390 2004; 6 2014; 29 2003; 278 2007; 78 2014; 23 1998; 392 2016; 34 2014; 20 1997; 388 1990; 40 2014; 129 2017; 74 1990; 335 2006; 21 2015; 86 2012; 27 2018; 33 2010; 5 2010; 30 2007; 69 2019; 7 2019; 34 1993; 43 2016; 167 2018; 109 2017; 373 2004; 304 2003; 299 2007; 13 2012; 109 2016; 12 2016; 11 2018; 24 2006; 355 2018; 17 2015; 2015 2003; 24 2014; 35 2005; 15 2016; 29 1988; 318 2016; 22 2018; 120 2017; 7 2017; 42 2004; 61 1996; 39 2013; 28 2000; 48 2002; 51 2015; 30 2013; 20 2015; 33 2005; 20 1995; 332 2017; 230 2011; 18 2017; 357 1998; 44 2013; 19 2013; 16 1996; 2018 2006; 66 2017; 32 1999; 14 2016; 86 2011; 26 2011; 27 2010; 74 2007; 27 2015; 1 2015; 14 2013; 47 2000; 157 2017; 26 1989; 333 2017; 25 2015; 11 2006; 5 2011; 37 2003 2019; 380 2012; 78 1983; 219 2019; 142 1988; 2 2015; 29 2004; 19 2015; 313 2017; 17 2015; 21 2017; 12 2019 2017; 18 2003; 60 2014; 71 e_1_2_12_6_1 e_1_2_12_2_1 e_1_2_12_17_1 e_1_2_12_111_1 e_1_2_12_115_1 e_1_2_12_108_1 e_1_2_12_20_1 e_1_2_12_66_1 e_1_2_12_43_1 e_1_2_12_85_1 e_1_2_12_24_1 Crosby NJ (e_1_2_12_90_1) 2003 e_1_2_12_47_1 e_1_2_12_89_1 e_1_2_12_62_1 e_1_2_12_81_1 e_1_2_12_100_1 e_1_2_12_28_1 e_1_2_12_104_1 e_1_2_12_31_1 e_1_2_12_77_1 e_1_2_12_54_1 e_1_2_12_96_1 e_1_2_12_35_1 e_1_2_12_58_1 e_1_2_12_12_1 e_1_2_12_73_1 e_1_2_12_50_1 e_1_2_12_92_1 e_1_2_12_3_1 e_1_2_12_18_1 e_1_2_12_110_1 e_1_2_12_114_1 e_1_2_12_21_1 e_1_2_12_44_1 e_1_2_12_63_1 e_1_2_12_86_1 e_1_2_12_107_1 e_1_2_12_25_1 e_1_2_12_48_1 e_1_2_12_67_1 e_1_2_12_40_1 e_1_2_12_82_1 e_1_2_12_122_1 e_1_2_12_29_1 e_1_2_12_103_1 e_1_2_12_119_1 e_1_2_12_32_1 e_1_2_12_55_1 e_1_2_12_74_1 e_1_2_12_97_1 e_1_2_12_36_1 e_1_2_12_59_1 e_1_2_12_78_1 e_1_2_12_13_1 e_1_2_12_7_1 e_1_2_12_51_1 e_1_2_12_70_1 e_1_2_12_93_1 e_1_2_12_4_1 e_1_2_12_19_1 e_1_2_12_38_1 Pignataro D (e_1_2_12_116_1) 1996; 2018 e_1_2_12_113_1 e_1_2_12_41_1 e_1_2_12_87_1 e_1_2_12_106_1 e_1_2_12_22_1 e_1_2_12_64_1 e_1_2_12_45_1 e_1_2_12_26_1 e_1_2_12_68_1 e_1_2_12_83_1 e_1_2_12_60_1 e_1_2_12_49_1 e_1_2_12_121_1 e_1_2_12_102_1 e_1_2_12_52_1 e_1_2_12_98_1 e_1_2_12_118_1 e_1_2_12_33_1 e_1_2_12_75_1 e_1_2_12_56_1 e_1_2_12_37_1 e_1_2_12_79_1 e_1_2_12_14_1 e_1_2_12_8_1 e_1_2_12_10_1 e_1_2_12_94_1 e_1_2_12_71_1 e_1_2_12_5_1 e_1_2_12_16_1 e_1_2_12_112_1 e_1_2_12_39_1 e_1_2_12_42_1 e_1_2_12_65_1 e_1_2_12_88_1 e_1_2_12_109_1 e_1_2_12_23_1 e_1_2_12_46_1 e_1_2_12_69_1 e_1_2_12_80_1 e_1_2_12_61_1 e_1_2_12_84_1 e_1_2_12_27_1 Lyons KE (e_1_2_12_95_1) 2019 e_1_2_12_101_1 e_1_2_12_120_1 e_1_2_12_105_1 e_1_2_12_30_1 e_1_2_12_53_1 e_1_2_12_76_1 e_1_2_12_99_1 e_1_2_12_117_1 e_1_2_12_34_1 e_1_2_12_57_1 e_1_2_12_15_1 e_1_2_12_91_1 e_1_2_12_11_1 e_1_2_12_72_1 e_1_2_12_9_1 |
| References_xml | – volume: 12 start-page: 175 year: 2016 article-title: Parkinsonism, movement disorders and genetics in frontotemporal dementia publication-title: Nat Rev Neurol – volume: 32 start-page: 1701 year: 2017 end-page: 09 article-title: Randomized, placebo‐controlled trial of ADS‐5102 (amantadine) extended‐release capsules for levodopa‐induced dyskinesia in Parkinson’s disease (EASE LID 3) publication-title: Mov Disord – volume: 38 start-page: 1184 year: 2006 end-page: 91 article-title: Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P‐type ATPase publication-title: Nat Genet – volume: 14 start-page: 572 year: 1999 end-page: 584 article-title: Core assessment program for surgical interventional therapies in Parkinson’s disease (CAPSIT‐PD) publication-title: Mov Disord – volume: 48 start-page: 938 year: 2000 end-page: 42 article-title: Predictors of nursing home placement in Parkinson’s disease: a population‐based, prospective study publication-title: J Am Geriatr Soc – volume: 43 start-page: 2227 year: 1993 end-page: 9 article-title: Risk factors for nursing home placement in advanced Parkinson’s disease publication-title: Neurology – volume: 386 start-page: 1683 year: 2015 end-page: 97 article-title: Lewy body dementias publication-title: Lancet Lond Engl – volume: 313 start-page: 584 year: 2015 end-page: 93 article-title: Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial publication-title: JAMA – volume: 21 start-page: 1703 year: 2006 end-page: 8 article-title: Levels of alpha‐synuclein mRNA in sporadic Parkinson disease patients publication-title: Mov Disord – volume: 27 start-page: 617 year: 2012 end-page: 26 article-title: Identifying prodromal Parkinson’s disease: pre‐motor disorders in Parkinson’s disease publication-title: Mov Disord – volume: 75 start-page: 157 year: 2015 end-page: 74 article-title: Catechol‐ ‐methyltransferase inhibitors in Parkinson’s disease publication-title: Drugs – volume: 27 start-page: 1276 year: 2012 end-page: 82 article-title: Caffeine and risk of Parkinson’s disease in a large cohort of men and women publication-title: Mov Disord – volume: 6 start-page: 435 year: 2004 end-page: 42 article-title: Demonstration of a role for alpha‐synuclein as a functional microtubule‐associated protein publication-title: J Alzheimers Dis – volume: 392 start-page: 605 year: 1998 end-page: 8 article-title: Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism publication-title: Nature – volume: 34 start-page: 1464 year: 2019 end-page: 70 article-title: Update of the MDS research criteria for prodromal Parkinson’s disease publication-title: Mov Disord – volume: 25 start-page: 41 year: 2017 end-page: 58 article-title: Atypical parkinsonian syndromes: a general neurologist’s perspective publication-title: Eur J Neurol – volume: 44 start-page: S53 year: 1998 end-page: 57 article-title: Genetics of Parkinson’s disease publication-title: Ann Neurol – volume: 22 start-page: 313 year: 2016 end-page: 22 article-title: Mechanism of deep brain stimulation publication-title: Neuroscientist – volume: 18 start-page: 1336 year: 2011 end-page: 42 article-title: NSAID use and risk of Parkinson disease: a population‐based case–control study publication-title: Eur J Neurol – volume: 35 start-page: 370 year: 2014 end-page: 84 article-title: Sex differences in Parkinson’s disease publication-title: Front Neuroendocrinol – volume: 380 start-page: 2307 year: 2019 end-page: 16 article-title: Targeting Huntingtin expression in patients with Huntington’s disease publication-title: N Engl J Med – volume: 304 start-page: 1158 year: 2004 end-page: 60 article-title: Hereditary early‐onset Parkinson’s disease caused by mutations in PINK1 publication-title: Science – volume: 16 start-page: 375 year: 2013 end-page: 7 article-title: Dangerous duet: LRRK2 and [alpha]‐synuclein jam at CMA publication-title: Nat Neurosci – volume: 26 start-page: S2 year: 2011 end-page: 41 article-title: The Movement Disorder Society evidence‐based medicine review update: treatments for the motor symptoms of Parkinson’s disease publication-title: Mov Disord – volume: 11 start-page: 625 year: 2015 article-title: Pathogenesis of Parkinson disease – the gut–brain axis and environmental factors publication-title: Nat Rev Neurol – volume: 29 start-page: 459 year: 2016 end-page: 66 article-title: How strong is the evidence that Parkinson’s disease is a prion disorder? publication-title: Curr Opin Neurol – year: 2019 – volume: 19 start-page: 508 year: 2013 end-page: 14 article-title: Safinamide reduces dyskinesias and prolongs L‐DOPA antiparkinsonian effect in parkinsonian monkeys publication-title: Parkinsonism Relat Disord – volume: 2 start-page: 1483 year: 1988 end-page: 4 article-title: Fetal dopamine‐rich mesencephalic grafts in Parkinson’s disease publication-title: Lancet Lond Engl – volume: 69 start-page: 1696 year: 2007 end-page: 700 article-title: Gout and risk of Parkinson disease: a prospective study publication-title: Neurology – volume: 230 start-page: 191 year: 2017 end-page: 212 article-title: Strategies for bringing stem cell‐derived dopamine neurons to the clinic – the NYSTEM trial publication-title: Prog Brain Res – volume: 31 start-page: 203 year: 2016 end-page: 13 article-title: Development of passive immunotherapies for synucleinopathies publication-title: Mov Disord – volume: 24 start-page: 197 year: 2003 end-page: 211 article-title: Staging of brain pathology related to sporadic Parkinson’s disease publication-title: Neurobiol Aging – volume: 20 start-page: 118 year: 2005 end-page: 9 article-title: Experimental evidence for a toxic etiology of tropical parkinsonism publication-title: Mov Disord – volume: 21 start-page: 1238 year: 2015 end-page: 42 article-title: Gout is not associated with a lower risk of Parkinson’s disease: a systematic review and meta‐analysis publication-title: Parkinsonism Relat Disord – volume: 74 start-page: 216 year: 2017 end-page: 24 article-title: Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations: a randomized clinical trial publication-title: JAMA Neurol – volume: 40 start-page: 1529 year: 1990 end-page: 34 article-title: Variable expression of Parkinson's disease: a base‐line analysis of the DAT ATOP cohort publication-title: Neurology – volume: 335 start-page: 948 year: 1990 end-page: 9 article-title: Parkinson’s disease publication-title: Lancet – volume: 11 start-page: 1443 year: 2015 end-page: 57 article-title: Genetic perspective on the role of the autophagy‐lysosome pathway in Parkinson disease publication-title: Autophagy – volume: 60 start-page: 69 year: 2003 end-page: 73 article-title: Randomized, double‐blind trial of glial cell line‐derived neurotrophic factor (GDNF) in PD publication-title: Neurology – volume: 142 start-page: 512 year: 2019 end-page: 25 article-title: Randomized trial of intermittent intraputamenal glial cell line‐derived neurotrophic factor in Parkinson’s disease publication-title: Brain – volume: 11 year: 2016 article-title: Association between Parkinson’s disease and cigarette smoking, rural living, well‐water consumption, farming and pesticide use: systematic review and meta‐analysis publication-title: PLoS One – volume: 15 start-page: 473 year: 2005 end-page: 90 article-title: Prevalence and incidence of Parkinson’s disease in Europe publication-title: Eur Neuropsychopharmacol J – volume: 278 start-page: 11753 year: 2003 end-page: 9 article-title: Aggregated and monomeric α‐synuclein bind to the S6′ proteasomal protein and inhibit proteasomal function publication-title: J Biol Chem – volume: 71 start-page: 543 year: 2014 end-page: 52 article-title: A randomized clinical trial of high‐dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit publication-title: JAMA Neurol – volume: 37 start-page: 228 year: 2011 end-page: 40 article-title: Mitochondria, calcium, and endoplasmic reticulum stress in Parkinson’s disease publication-title: BioFactors Oxf Engl – volume: 109 start-page: 249 year: 2018 end-page: 57 article-title: Alpha‐synuclein: pathology, mitochondrial dysfunction and neuroinflammation in Parkinson’s disease publication-title: Neurobiol Dis – volume: 129 start-page: 71 year: 2014 end-page: 9 article-title: Parkinson’s disease and risk of mortality: meta‐analysis and systematic review publication-title: Acta Neurol Scand – volume: 219 start-page: 979 year: 1983 end-page: 80 article-title: Chronic parkinsonism in humans due to a product of meperidine‐analog synthesis publication-title: Science – volume: 30 start-page: 90 year: 2015 end-page: 102 article-title: Behavioral effects of levodopa publication-title: Mov Disord – volume: 51 start-page: 296 year: 2002 end-page: 301 article-title: A new locus for Parkinson’s disease (PARK8) maps to chromosome 12p11.2–q13.1 publication-title: Ann Neurol – volume: 17 start-page: 804 year: 2018 end-page: 22 article-title: Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs publication-title: Nat Rev Drug Discov – volume: 27 start-page: 9220 year: 2007 end-page: 32 article-title: Different species of alpha‐synuclein oligomers induce calcium influx and seeding publication-title: J Neurosci – volume: 357 start-page: 891 year: 2017 end-page: 8 article-title: β2‐adrenoreceptor is a regulator of the α‐synuclein gene driving risk of Parkinson’s disease publication-title: Science – volume: 318 start-page: 51 year: 1988 article-title: Transplantation of fetal substantia nigra and adrenal medulla to the caudate nucleus in two patients with Parkinson’s disease publication-title: N Engl J Med – volume: 7 start-page: 1398 year: 2017 article-title: Brain iron chelation by deferiprone in a phase 2 randomised double‐blinded placebo controlled clinical trial in Parkinson’s disease publication-title: Sci Rep – volume: 333 start-page: 1269 year: 1989 article-title: Mitochondrial complex I deficiency in Parkinson’s disease publication-title: Lancet – volume: 20 start-page: 16 year: 2013 end-page: 34 article-title: EFNS/MDS‐ES/ENS [corrected] recommendations for the diagnosis of Parkinson’s disease publication-title: Eur J Neurol – volume: 18 start-page: 435 year: 2017 end-page: 50 article-title: Non‐motor features of Parkinson disease publication-title: Nat Rev Neurosci – volume: 390 start-page: 1664 year: 2017 end-page: 75 article-title: Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double‐blind, placebo‐controlled trial publication-title: Lancet – volume: 33 start-page: 75 year: 2018 end-page: 87 article-title: Consensus statement on the classification of tremors. From the task force on tremor of the International Parkinson and Movement Disorder Society publication-title: Mov Disord – volume: 11 year: 2016 article-title: Statin use and the risk of Parkinson’s disease: an updated meta‐analysis publication-title: PLoS One – volume: 7 start-page: 219 year: 2017 end-page: 33 article-title: VPS35, the retromer complex and Parkinson’s disease publication-title: J Park Dis – volume: 29 start-page: 75 year: 2014 end-page: 82 article-title: Double‐blind study of the actively transported levodopa prodrug XP21279 in Parkinson’s disease publication-title: Mov Disord – volume: 17 start-page: 34 year: 2017 article-title: Subtypes of Parkinson’s disease: what do they tell us about disease progression? publication-title: Curr Neurol Neurosci Rep – volume: 30 start-page: 1591 year: 2015 end-page: 601 article-title: MDS clinical diagnostic criteria for Parkinson’s disease publication-title: Mov Disord – volume: 78 start-page: 1304 year: 2007 end-page: 9 article-title: Estimated life expectancy of Parkinson’s patients compared with the UK population publication-title: J Neurol Neurosurg Psychiatry – volume: 42 start-page: 1 year: 2017 end-page: 11 article-title: Hyperechogenicity of substantia nigra for differential diagnosis of Parkinson’s disease: a meta‐analysis publication-title: Parkinsonism Relat Disord – volume: 61 start-page: 561 year: 2004 end-page: 6 article-title: A controlled, randomized, delayed‐start study of rasagiline in early Parkinson disease publication-title: Arch Neurol – volume: 39 start-page: 37 year: 1996 end-page: 45 article-title: Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP patients requiring levodopa publication-title: Ann Neurol – volume: 26 start-page: 1218 year: 2011 end-page: 24 article-title: Meta‐analysis of 123I‐MIBG cardiac scintigraphy for the diagnosis of Lewy body‐related disorders publication-title: Mov Disord – volume: 29 start-page: 166 year: 2014 end-page: 8 article-title: Nonmotor symptoms and health‐related quality of life in early Parkinson’s disease publication-title: Mov Disord – volume: 128 start-page: 166 year: 2013 end-page: 71 article-title: Inhaled dry powder apomorphine (VR040) for ‘off’ periods in Parkinson’s disease: an in‐clinic double‐blind dose ranging study publication-title: Acta Neurol Scand – volume: 88 start-page: 2198 year: 2017 end-page: 206 article-title: Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease publication-title: Neurology – year: 2019 article-title: Prodromal Parkinson’s disease: the decade past, the decade to come publication-title: Mov Disord – volume: 167 start-page: 1469 year: 2016 end-page: 1480 article-title: Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease publication-title: Cell – volume: 1 start-page: 15005 year: 2015 article-title: Huntington disease publication-title: Nat Rev Dis Primer – volume: 78 start-page: 1096 year: 2012 end-page: 9 article-title: Amantadine: the journey from fighting flu to treating Parkinson disease publication-title: Neurology – volume: 5 year: 2010 article-title: Alpha‐synuclein suppression by targeted small interfering RNA in the primate substantia nigra publication-title: PLoS One – volume: 86 start-page: S13 year: 2016 end-page: 24 article-title: Advances in levodopa therapy for Parkinson disease: review of RYTARY (carbidopa and levodopa) clinical efficacy and safety publication-title: Neurology – volume: 19 start-page: 603 year: 2004 end-page: 4 article-title: Atypical parkinsonism and Annonaceae consumption in New Caledonia publication-title: Mov Disord – volume: 29 start-page: 433 year: 2015 end-page: 41 article-title: Defining the role of the monoamine oxidase‐B inhibitors for Parkinson’s disease publication-title: CNS Drugs – volume: 38 start-page: 515 year: 2006 end-page: 7 article-title: High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease publication-title: Nat Genet – volume: 31 start-page: 1366 year: 2016 end-page: 72 article-title: Sublingual apomorphine (APL‐130277) for the acute conversion of OFF to ON in Parkinson’s disease publication-title: Mov Disord – volume: 12 year: 2017 article-title: Therapeutic potential of autophagy‐enhancing agents in Parkinson’s disease publication-title: Mol Neurodegener – volume: 66 start-page: 983 year: 2006 end-page: 95 article-title: Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence‐based review): report of the Quality Standards Subcommittee of the American Academy of Neurology publication-title: Neurology – volume: 28 start-page: 668 year: 2013 end-page: 70 article-title: How to identify tremor dominant and postural instability/gait difficulty groups with the Movement Disorder Society Unified Parkinson’s Disease Rating Scale: comparison with the Unified Parkinson’s Disease Rating Scale publication-title: Mov Disord – volume: 2018 start-page: 575 year: 1996 end-page: 89 article-title: Gene therapy approaches in the non‐human primate model of Parkinson’s disease publication-title: J Neural Transm Vienna Austria – volume: 368 start-page: 610 year: 2013 end-page: 22 article-title: Neurostimulation for Parkinson’s disease with early motor complications publication-title: N Engl J Med – volume: 120 start-page: 149 year: 2018 end-page: 63 article-title: Unhealthy gut, unhealthy brain: the role of the intestinal microbiota in neurodegenerative diseases publication-title: Neurochem Int – volume: 299 start-page: 256 year: 2003 end-page: 9 article-title: Mutations in the DJ‐1 gene associated with autosomal recessive early‐onset parkinsonism publication-title: Science – volume: 47 start-page: 495 year: 2013 end-page: 508 article-title: The Lewy body in Parkinson’s disease and related neurodegenerative disorders publication-title: Mol Neurobiol – volume: 13 start-page: 67 year: 2007 end-page: 76 article-title: Exploring the relationship between essential tremor and Parkinson’s disease publication-title: Parkinsonism Relat Disord – volume: 5 start-page: 677 year: 2006 end-page: 87 article-title: Continuous dopamine‐receptor treatment of Parkinson’s disease: scientific rationale and clinical implications publication-title: Lancet Neurol – volume: 27 start-page: 907 year: 2011 end-page: 19 article-title: Levodopa‐carbidopa intestinal gel for treatment of advanced Parkinson’s disease publication-title: Curr Med Res Opin – volume: 48 start-page: 1277 year: 1997 end-page: 81 article-title: A population perspective on diagnostic criteria for Parkinson’s disease publication-title: Neurology – volume: 157 start-page: 401 year: 2000 end-page: 10 article-title: Alpha‐synuclein promotes mitochondrial deficit and oxidative stress publication-title: Am J Pathol – volume: 78 start-page: 696 year: 2012 end-page: 701 article-title: Role of DaTSCAN and clinical diagnosis in Parkinson disease publication-title: Neurology – volume: 30 start-page: 1222 year: 2015 end-page: 8 article-title: Gastroretentive carbidopa/levodopa, DM‐1992, for the treatment of advanced Parkinson’s disease publication-title: Mov Disord – volume: 7 start-page: S67 year: 2019 article-title: Challenges in the diagnosis of Wilson disease publication-title: Ann Transl Med – volume: 74 start-page: 995 year: 2010 end-page: 1002 article-title: Anti‐inflammatory drugs and risk of Parkinson disease: a meta‐analysis publication-title: Neurology – volume: 33 start-page: 39 year: 2015 end-page: 56 article-title: Atypical parkinsonism: diagnosis and treatment publication-title: Neurol Clin – volume: 14 start-page: 795 year: 2015 end-page: 803 article-title: Exploratory Trials in Parkinson Disease (NET‐PD) FS‐ZONE Investigators. Pioglitazone in early Parkinson’s disease: a phase 2, multicentre, double‐blind, randomised trial publication-title: Lancet Neurol – volume: 86 start-page: 767 year: 2015 end-page: 73 article-title: Cholinesterase inhibitors for Parkinson’s disease: a systematic review and meta‐analysis publication-title: J Neurol Neurosurg Psychiatry – volume: 28 start-page: 1064 year: 2013 end-page: 71 article-title: Factors predictive of the development of levodopa‐induced dyskinesia and wearing‐off in Parkinson’s disease publication-title: Mov Disord – volume: 34 start-page: 955 year: 2016 end-page: 65 article-title: Epidemiology of Parkinson disease publication-title: Neurol Clin – volume: 373 start-page: 173 year: 2017 end-page: 8 article-title: Neuropsychiatric symptoms, behavioural disorders, and quality of life in Parkinson’s disease publication-title: J Neurol Sci – start-page: CD003467 year: 2003 article-title: Amantadine for dyskinesia in Parkinson’s disease publication-title: Cochrane Database Syst Rev – volume: 30 start-page: 8083 year: 2010 end-page: 95 article-title: A pathologic cascade leading to synaptic dysfunction in alpha‐synuclein‐induced neurodegeneration publication-title: J Neurosci – volume: 23 start-page: 387 year: 2014 end-page: 410 article-title: Dopamine receptor agonists for Parkinson’s disease publication-title: Expert Opin Investig Drugs – volume: 20 start-page: 808 year: 2014 end-page: 14 article-title: Differentiating drug‐induced parkinsonism from Parkinson’s disease: an update on non‐motor symptoms and investigations publication-title: Parkinsonism Relat Disord – volume: 2015 start-page: 1 year: 2015 end-page: 7 article-title: Reduced risk of Parkinson’s disease in users of calcium channel blockers: a meta‐analysis publication-title: Int J Chronic Dis – volume: 24 start-page: 540 year: 2018 end-page: 59 article-title: Glucocerebrosidase and Parkinson disease: molecular, clinical, and therapeutic implications publication-title: Neuroscientist – volume: 109 start-page: 9611 year: 2012 end-page: 6 article-title: Loss of P‐type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration publication-title: Proc Natl Acad Sci – volume: 332 start-page: 1118 year: 1995 end-page: 24 article-title: Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson’s disease publication-title: N Engl J Med – volume: 17 start-page: 597 year: 2018 end-page: 608 article-title: LRP10 genetic variants in familial Parkinson’s disease and dementia with Lewy bodies: a genome‐wide linkage and sequencing study publication-title: Lancet Neurol – start-page: 1 year: 2019 end-page: 11 article-title: Changing the treatment paradigm for Parkinson’s disease psychosis with pimavanserin publication-title: Expert Rev Clin Pharmacol – volume: 388 start-page: 839 year: 1997 end-page: 40 article-title: Alpha‐synuclein in Lewy bodies publication-title: Nature – volume: 276 start-page: 2045 year: 1997 end-page: 7 article-title: Mutation in the alpha‐synuclein gene identified in families with Parkinson’s disease publication-title: Science – volume: 355 start-page: 896 year: 2006 end-page: 908 article-title: A randomized trial of deep‐brain stimulation for Parkinson’s disease publication-title: N Engl J Med – volume: 26 start-page: 1551 year: 2017 end-page: 9 article-title: Cell therapy for Parkinson’s disease publication-title: Cell Transplant – ident: e_1_2_12_48_1 doi: 10.1016/j.neuint.2018.08.005 – ident: e_1_2_12_9_1 doi: 10.1002/mds.20300 – ident: e_1_2_12_72_1 doi: 10.1016/j.parkreldis.2017.06.006 – ident: e_1_2_12_82_1 doi: 10.1111/ane.12107 – ident: e_1_2_12_53_1 doi: 10.1038/nrn.2017.62 – ident: e_1_2_12_79_1 doi: 10.1002/mds.25742 – ident: e_1_2_12_39_1 doi: 10.1080/15548627.2015.1067364 – ident: e_1_2_12_77_1 doi: 10.1212/WNL.0000000000002510 – ident: e_1_2_12_119_1 doi: 10.1056/NEJM198801073180115 – ident: e_1_2_12_112_1 doi: 10.1016/S0140-6736(17)31585-4 – ident: e_1_2_12_94_1 doi: 10.1038/nrd.2018.136 – ident: e_1_2_12_46_1 doi: 10.3233/JPD-161020 – ident: e_1_2_12_74_1 doi: 10.1002/mds.26121 – ident: e_1_2_12_98_1 doi: 10.1002/1531-8257(199907)14:4<572::AID-MDS1005>3.0.CO;2-C – ident: e_1_2_12_114_1 doi: 10.1002/mds.26481 – ident: e_1_2_12_104_1 doi: 10.1016/S1474-4422(15)00144-1 – ident: e_1_2_12_49_1 doi: 10.1111/ene.12022 – ident: e_1_2_12_80_1 doi: 10.1002/mds.26219 – ident: e_1_2_12_57_1 doi: 10.1002/mds.27670 – ident: e_1_2_12_24_1 doi: 10.3233/JAD-2004-6412 – ident: e_1_2_12_78_1 doi: 10.1185/03007995.2011.560146 – ident: e_1_2_12_120_1 doi: 10.1056/NEJM199504273321702 – ident: e_1_2_12_71_1 doi: 10.1002/mds.23659 – start-page: 1 year: 2019 ident: e_1_2_12_95_1 article-title: Changing the treatment paradigm for Parkinson’s disease psychosis with pimavanserin publication-title: Expert Rev Clin Pharmacol – ident: e_1_2_12_100_1 doi: 10.1136/jnnp.2006.100107 – ident: e_1_2_12_102_1 doi: 10.1111/j.1532-5415.2000.tb06891.x – ident: e_1_2_12_52_1 doi: 10.1007/s11910-017-0738-x – ident: e_1_2_12_97_1 doi: 10.1056/NEJMoa060281 – ident: e_1_2_12_60_1 doi: 10.1016/j.parkreldis.2014.05.011 – ident: e_1_2_12_70_1 doi: 10.1212/WNL.0b013e318248e520 – ident: e_1_2_12_11_1 doi: 10.1002/mds.25076 – ident: e_1_2_12_103_1 doi: 10.1212/WNL.43.11.2227 – ident: e_1_2_12_45_1 doi: 10.1016/S1474-4422(18)30179-0 – ident: e_1_2_12_107_1 doi: 10.1001/jamaneurol.2014.131 – ident: e_1_2_12_122_1 doi: 10.1016/bs.pbr.2017.02.008 – ident: e_1_2_12_109_1 doi: 10.1001/jama.2015.120 – ident: e_1_2_12_75_1 doi: 10.1016/S1474-4422(06)70521-X – ident: e_1_2_12_25_1 doi: 10.1523/JNEUROSCI.1091-10.2010 – ident: e_1_2_12_117_1 doi: 10.1371/journal.pone.0012122 – ident: e_1_2_12_73_1 doi: 10.1002/mds.23829 – ident: e_1_2_12_58_1 doi: 10.1002/mds.27802 – ident: e_1_2_12_41_1 doi: 10.1038/nn.3361 – ident: e_1_2_12_35_1 doi: 10.1126/science.1096284 – ident: e_1_2_12_42_1 doi: 10.1073/pnas.1112368109 – ident: e_1_2_12_91_1 doi: 10.1212/01.wnl.0000215250.82576.87 – ident: e_1_2_12_108_1 doi: 10.1002/ana.410390107 – ident: e_1_2_12_88_1 doi: 10.1136/jnnp-2014-308764 – ident: e_1_2_12_6_1 doi: 10.1371/journal.pone.0151841 – ident: e_1_2_12_83_1 doi: 10.1002/mds.26697 – ident: e_1_2_12_31_1 doi: 10.1126/science.276.5321.2045 – ident: e_1_2_12_27_1 doi: 10.1016/S0197-4580(02)00065-9 – ident: e_1_2_12_28_1 doi: 10.1097/WCO.0000000000000349 – ident: e_1_2_12_76_1 doi: 10.1002/mds.25364 – ident: e_1_2_12_19_1 doi: 10.1007/s12035-012-8280-y – ident: e_1_2_12_85_1 doi: 10.1001/jamaneurol.2016.4467 – ident: e_1_2_12_30_1 doi: 10.1016/j.cell.2016.11.018 – ident: e_1_2_12_101_1 doi: 10.1111/ane.12201 – ident: e_1_2_12_64_1 doi: 10.1111/ene.13412 – ident: e_1_2_12_89_1 doi: 10.1212/WNL.0b013e31824e8f0d – ident: e_1_2_12_115_1 doi: 10.1186/s13024-017-0154-3 – ident: e_1_2_12_5_1 doi: 10.1016/j.yfrne.2014.02.002 – ident: e_1_2_12_65_1 doi: 10.1016/S0140-6736(15)00462-6 – ident: e_1_2_12_17_1 doi: 10.1016/j.parkreldis.2015.08.030 – ident: e_1_2_12_26_1 doi: 10.1016/0140-6736(90)91006-V – ident: e_1_2_12_67_1 doi: 10.21037/atm.2019.02.10 – ident: e_1_2_12_69_1 doi: 10.1056/NEJMoa1900907 – ident: e_1_2_12_121_1 doi: 10.1177/0963689717735411 – ident: e_1_2_12_21_1 doi: 10.1016/S0002-9440(10)64553-1 – ident: e_1_2_12_92_1 doi: 10.1002/mds.27131 – ident: e_1_2_12_55_1 doi: 10.1016/j.jns.2016.12.060 – ident: e_1_2_12_63_1 doi: 10.1016/j.ncl.2014.09.012 – ident: e_1_2_12_22_1 doi: 10.1074/jbc.M208641200 – ident: e_1_2_12_29_1 doi: 10.1038/nrneurol.2015.197 – ident: e_1_2_12_38_1 doi: 10.1038/ng1769 – ident: e_1_2_12_99_1 doi: 10.1056/NEJMoa1205158 – ident: e_1_2_12_3_1 doi: 10.1016/j.ncl.2016.06.012 – ident: e_1_2_12_110_1 doi: 10.1093/brain/awz023 – ident: e_1_2_12_62_1 doi: 10.1016/j.parkreldis.2006.05.033 – ident: e_1_2_12_13_1 doi: 10.1371/journal.pone.0152564 – ident: e_1_2_12_2_1 doi: 10.1212/WNL.48.5.1277 – ident: e_1_2_12_68_1 doi: 10.1038/nrdp.2015.5 – ident: e_1_2_12_84_1 doi: 10.1007/s40263-015-0249-8 – ident: e_1_2_12_96_1 doi: 10.1177/1073858415581986 – ident: e_1_2_12_66_1 doi: 10.1038/nrneurol.2016.14 – ident: e_1_2_12_93_1 doi: 10.1212/WNL.0000000000004003 – ident: e_1_2_12_34_1 doi: 10.1016/S0140-6736(89)92366-0 – ident: e_1_2_12_54_1 doi: 10.1002/mds.25799 – ident: e_1_2_12_113_1 doi: 10.1038/s41598-017-01402-2 – ident: e_1_2_12_51_1 doi: 10.1002/mds.25383 – ident: e_1_2_12_50_1 doi: 10.1212/WNL.40.10.1529 – ident: e_1_2_12_12_1 doi: 10.1155/2015/697404 – ident: e_1_2_12_56_1 doi: 10.1002/mds.24996 – ident: e_1_2_12_40_1 doi: 10.1002/ana.10113 – ident: e_1_2_12_47_1 doi: 10.1002/biof.159 – ident: e_1_2_12_105_1 doi: 10.1001/archneur.61.4.561 – ident: e_1_2_12_10_1 doi: 10.1126/science.aaf3934 – ident: e_1_2_12_20_1 doi: 10.1002/ana.67 – ident: e_1_2_12_87_1 doi: 10.1007/s40265-014-0343-0 – ident: e_1_2_12_59_1 doi: 10.1002/mds.26424 – ident: e_1_2_12_111_1 doi: 10.1212/WNL.90.15_supplement.P2.039 – ident: e_1_2_12_8_1 doi: 10.1002/mds.20104 – ident: e_1_2_12_106_1 doi: 10.1212/WNL.60.1.69 – ident: e_1_2_12_14_1 doi: 10.1111/j.1468-1331.2011.03399.x – ident: e_1_2_12_4_1 doi: 10.1016/j.euroneuro.2005.04.007 – ident: e_1_2_12_44_1 doi: 10.1177/1073858417748875 – ident: e_1_2_12_118_1 doi: 10.1016/S0140-6736(88)90950-6 – ident: e_1_2_12_23_1 doi: 10.1523/JNEUROSCI.2617-07.2007 – ident: e_1_2_12_86_1 doi: 10.1016/j.parkreldis.2013.01.009 – ident: e_1_2_12_43_1 doi: 10.1038/ng1884 – ident: e_1_2_12_16_1 doi: 10.1212/01.wnl.0000279518.10072.df – ident: e_1_2_12_7_1 doi: 10.1126/science.6823561 – ident: e_1_2_12_15_1 doi: 10.1212/WNL.0b013e3181d5a4a3 – ident: e_1_2_12_36_1 doi: 10.1038/33416 – volume: 2018 start-page: 575 year: 1996 ident: e_1_2_12_116_1 article-title: Gene therapy approaches in the non‐human primate model of Parkinson’s disease publication-title: J Neural Transm Vienna Austria – ident: e_1_2_12_37_1 doi: 10.1126/science.1077209 – ident: e_1_2_12_18_1 doi: 10.1002/ana.410440708 – ident: e_1_2_12_81_1 doi: 10.1517/13543784.2014.869209 – start-page: CD003467 year: 2003 ident: e_1_2_12_90_1 article-title: Amantadine for dyskinesia in Parkinson’s disease publication-title: Cochrane Database Syst Rev – ident: e_1_2_12_33_1 doi: 10.1002/mds.21007 – ident: e_1_2_12_32_1 doi: 10.1016/j.nbd.2017.04.004 – ident: e_1_2_12_61_1 doi: 10.1002/mds.27121 |
| SSID | ssj0002720 |
| Score | 2.717989 |
| SecondaryResourceType | review_article |
| Snippet | Parkinson disease (PD) is the most common neurodegenerative movement disorder. In Europe, prevalence and incidence rates for PD are estimated at approximately... |
| SourceID | proquest pubmed crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 27 |
| SubjectTerms | Akinesia Brain diseases clinical Diagnosis Differential diagnosis Dopamine receptors Environmental factors Europe Genetics Humans Incidence Inclusion bodies Inclusions Lewy bodies Motor task performance Movement disorders neurodegeneration Neurodegenerative diseases Parkinson disease Parkinson Disease - diagnosis Parkinson Disease - epidemiology Parkinson Disease - etiology Parkinson Disease - therapy Parkinson's disease Pathogenesis pathophysiology Prevalence Rigidity Risk analysis Risk Factors Signs and symptoms Substantia nigra Substantia Nigra - metabolism Substantia Nigra - pathology Synuclein treatment Tremor |
| Title | Parkinson disease |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fene.14108 https://www.ncbi.nlm.nih.gov/pubmed/31631455 https://www.proquest.com/docview/2322135403 https://www.proquest.com/docview/2307399479 |
| Volume | 27 |
| WOSCitedRecordID | wos000498644200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library Free Content customDbUrl: eissn: 1468-1331 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002720 issn: 1351-5101 databaseCode: WIN dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1468-1331 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002720 issn: 1351-5101 databaseCode: DRFUL dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEB7WVcSLru_6WFbx4KXSpkmb4El0FwUtIi7urSRtCoJ0ZR_-fjPpAxcVBE8tdEpeM5NvMpkZgDOW-ZJEShj5zqhLRea7MhTazdGFlfqhEpGyxSaiOOajkXhswWUdC1Pmh2gO3FAyrL5GAZdq-kXIjSq4wEuKGOhrnli94OUubrQw-hetscV8F_muyiqEt3iaPxf3om8AcxGv2g1nsPGvrnZgvcKZvauSMTahpYstWH2oPOnb0MFwZxv51at8NDswHPSfr2_dqjyCm1JfGDVFMlQRlBAlmRFDTnNlzB9OmfJ0xM2-nIeMad9XglNNc55KYx_IMMgQRDEv2IV2MS70PvQUYTyKZJinRFLlhcqAKE08mmljLeVe6MB5PVFJWuUOxxIWb0ltQ5ghJnaIDpw2pO9lwoyfiI7q2U4qmZkmBtsRH4-hAgdOms-G29GFIQs9niMNehYFjYQDe-UqNa0EBlpi2nXTWbsYvzef9OO-fTn4O-khrBE0te3pyxG0Z5O5PoaV9GP2Op10YSka8S4s3zwNhvddy4mfOhbX0A |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS8MwED_mFPVF53d16hQffKm0adom4IvIxoZb8WHi3krSpiBIJ_vw7zeXfqCoIPhW6IV83V1-d5fcAVz5qStIKLmW75TalKeuLQKu7AxDWIkbSB5KU2wijCI2mfDHBtxWb2GK_BC1ww0lw-hrFHB0SH-Scq0LbvCWIluBVaqBBhZueB5EtR7GCKMxt3zXRs4r8wrhPZ666dfT6BvE_IpYzZHT2_7fYFuwVULNzl3BGzvQUPkurI_KYPoetPDFs3n81SnDNPvw1OuO7_t2WSHBTqjLtaYiKWoJSogUvpZERjOpLSBGfemokOmjOQt8X7mu5IwqmrFEaBNBBF6KOMp3vANo5tNcHUFHEp-FoQiyhAgqnUBqHKWIQ1OlDabMCSy4rlYqTsr04VjF4jWuzAg9xdhM0YLLmvStyJnxE1G7Wu64FJt5rOEdcdET5VlwUf_WDI9RDJGr6RJpMLjIacgtOCy2qe7F0-gSM6_rwZrd-L37uBt1zcfx30nPYaM_Hg3j4SB6OIFNgpa3cca0obmYLdUprCXvi5f57Mww4gf4Odlm |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS8MwED_mJuKLzu_q1Ck--FJp07RNwBdxK4qzDHGwt9K0KQjSjX3495tLP3CoIPhW6IV83V1-d5fcAVy5qR0TX3Al3yk1KU9tM_a4NDMMYSW2J7gvdLEJPwzZeMyHDbit3sIU-SFqhxtKhtbXKOBymmZfpFzpghu8pcjWoEWxiEwTWr2XYDSoNTHGGLXB5dom8l6ZWQhv8tSNV8-jbyBzFbPqQyfY_t9w27BVgs3uXcEdO9CQ-S5sPJfh9D1o45tn_fyrWwZq9mEU9F_vH8yyRoKZUJsrXUVS1BOUEBG7ShYZzYSygRh1hSV9pg7nzHNdaduCMyppxpJYGQmx56SIpFzLOYBmPsnlEXQFcZnvx16WkJgKyxMKSUli0VQqkymzPAOuq5WKkjKBONaxeI8qQ0JNMdJTNOCyJp0WWTN-IupUyx2VgjOPFMAjNvqiHAMu6t-K5TGOEedyskQaDC9y6nMDDottqntxFL7E3OtqsHo3fu8-6od9_XH8d9Jz2Bj2gmjwGD6dwCZB01t7YzrQXMyW8hTWk4_F23x2VnLiJ0DK2g8 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Parkinson+disease&rft.jtitle=European+journal+of+neurology&rft.au=Balestrino%2C+R.&rft.au=Schapira%2C+A.H.V.&rft.date=2020-01-01&rft.issn=1351-5101&rft.eissn=1468-1331&rft.volume=27&rft.issue=1&rft.spage=27&rft.epage=42&rft_id=info:doi/10.1111%2Fene.14108&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_ene_14108 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1351-5101&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1351-5101&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1351-5101&client=summon |